==== Front
Int J Mol Sci
Int J Mol Sci
ijms
International Journal of Molecular Sciences
1422-0067 MDPI 

33287221
10.3390/ijms21239221
ijms-21-09221
Case Report
Targeting the pH Paradigm at the Bedside: A Practical Approach
Koltai Tomas  Centro de Diagnostico y Tratamiento de la Obra Social del Personal de la Alimentacion, Talar de Pacheco, Buenos Aires 1617, Argentina; tkoltai@hotmail.com
03 12 2020 
12 2020 
21 23 922112 11 2020 28 11 2020 © 2020 by the author.2020Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).The inversion of the pH gradient in malignant tumors, known as the pH paradigm, is increasingly becoming accepted by the scientific community as a hallmark of cancer. Accumulated evidence shows that this is not simply a metabolic consequence of a dysregulated behavior, but rather an essential process in the physiopathology of accelerated proliferation and invasion. From the over-simplification of increased lactate production as the cause of the paradigm, as initially proposed, basic science researchers have arrived at highly complex and far-reaching knowledge, that substantially modified that initial belief. These new developments show that the paradigm entails a different regulation of membrane transporters, electrolyte exchangers, cellular and membrane enzymes, water trafficking, specialized membrane structures, transcription factors, and metabolic changes that go far beyond fermentative glycolysis. This complex world of dysregulations is still shuttered behind the walls of experimental laboratories and has not yet reached bedside medicine. However, there are many known pharmaceuticals and nutraceuticals that are capable of targeting the pH paradigm. Most of these products are well known, have low toxicity, and are also inexpensive. They need to be repurposed, and this would entail shorter clinical studies and enormous cost savings if we compare them with the time and expense required for the development of a new molecule. Will targeting the pH paradigm solve the “cancer problem”? Absolutely not. However, reversing the pH inversion would strongly enhance standard treatments, rendering them more efficient, and in some cases permitting lower doses of toxic drugs. This article’s goal is to describe how to reverse the pH gradient inversion with existing drugs and nutraceuticals that can easily be used in bedside medicine, without adding toxicity to established treatments. It also aims at increasing awareness among practicing physicians that targeting the pH paradigm would be able to improve the results of standard therapies. Some clinical cases will be presented as well, showing how the pH gradient inversion can be treated at the bedside in a simple manner with repurposed drugs.

pH paradigmpHtomeamilorideproton pump inhibitorsacetazolamidetopiramatequercetinrepurposed drugs
==== Body
1. Introduction
Between 1980 and 2000, with the identification of protooncogenes, tumor suppressor genes, metabolic and signaling pathways and the many proteins involved in cancer’s development and progression, the general belief was that cancer is a chaotic process [1]. 

However, in 1996, Kinzler and Vogelstein [2] after many years of meticulous work described the step-by-step genetic evolution of colon cancer from adenoma to invasive disease. Thus, cancer was not so chaotic. In 2000, two distinguished researchers, worried by this vision of random development of malignancies, published their seminal paper “The Hallmarks of Cancer” [3]. This review showed for the first time that malignant tumors are quite well organized and follow certain basic rules. The authors, Hanahan and Weinberg, described six hallmarks that all cancer cells follow in order to become malignant and progress. In a further paper, in 2011, they added two more hallmarks and two other necessary conditions to be fulfilled [4]. 

Actually, these ten rules have become the keystone of cancer research in the last ten years and show how well organized malignant transformation and progression is. There is considerable organization behind the apparent chaos, and this organization is shared by many tumors independently of where they originate.

In the meantime, a group of researchers has been steadily investigating what we may call the eleventh hallmark of cancer: the inversion of the pH gradient—the pH paradigm.

This paradigm consists of slightly increased alkalinity of the intracellular milieu, while the extracellular substance becomes very acidic. This means that the normal pH gradient is inverted in cancer cells. Does this deserve to be considered another hallmark?

We think it does, because of its universality and the fact that proliferation, invasion, and metastatic potential are significantly reduced by reversing the inverted gradient. Furthermore, when the first step of the inversion is blocked, malignant transformation does not occur [5]. 

2. A Short History of the pH Paradigm
The pH paradigm in cancer is a structure that, like other concepts in science, has been built up brick-by-brick. After one hundred years of research on this subject, we now finally have a full understanding of its importance. We also know the basic mechanisms that lead to the paradigm. However, this knowledge is incomplete as yet.

Importantly, we know how to tame and reverse the paradigm. The importance of reversing the inversion of the pH gradient is looming. Animal experiments and an as yet limited number of human cases are showing the potential of this type of treatment. 

Interest in tumors’ pH stems from the pioneering works by Otto Warburg almost a hundred years ago, when he found that tumors were acidic. He was unable to distinguish between intracellular and extracellular pH at that time [6]. In 1975, Leopoldo Anghileri [7] found that inducing metabolic acidosis with ammonium chloride decreased the growth of many experimental tumors. The mechanism involved was not clarified.

In 1980, Harguindey and Gillis proposed for the first time that proton alterations in the cancer environment had a relationship with carcinogenesis and the active interference with these alterations could prevent/modify carcinogenesis [8].

The studies by Albers et al. [9] in 1981 were the first to show that there was an inversion of the pH gradient in malignant tumors. They wrote: “pHi exceeded pHe if either PCO2 and/or the concentration of lactic acid were raised above a critical level”. However, the authors expressed doubts about their own results. This publication did bring three new concepts to light: ⁂ The pH gradient inversion in cancer,

⁂ That lactic acid was not the only cause of acidity, with CO2 being equally important, and

⁂ That pHi and pHe are different.



This was the starting point.

The conclusion of metabolic and physiopathologic studies on the pH gradient inversion showed that it was an essential step in cancerization and tumor progression. It should not be recognized as a hallmark if the paradigm is only a side effect of the Warburg effect [10]. It is not, because pH inversion seems to take place before the Warburg effect is functionally operative, and it is not dependent only on increased lactate production [11]. Further research is needed to determine what comes first, the Warburg effect or the pH paradigm. However, after the seminal studies by the groups headed by Pouyssegur [12,13,14,15], and Reshkin [5,16,17,18,19,20,21], evidence hints towards the second option, based on:(a) The finding of increased intracellular alkalinity at the very beginning of malignization [5].

(b) The need for a high intracellular pH for the increased activity of glycolytic enzymes [22].

(c) The persistence of the pH paradigm, even in conditions in which lactic acid cannot be produced.

(d) The Warburg effect (aerobic glycolysis) is not indispensable for tumor survival and progression [13].

(e) Hypoxia is involved in both the Warburg effect and pH inversion. Its signaling through hypoxia-inducible factors (HIFs) induces not only the overexpression of almost all the glycolytic enzymes, but the exchangers and transporters that generate the gradient inversion as well [23].

(f) Intracellular pH controls growth in amniote embryos [24].



We think that both these essential hallmarks of cancer, namely the gradient inversion and aerobic glycolysis (Warburg effect), are parallel processes with many intersecting paths. HIFs are part of this network and probably, hypoxia coordinates the process as a major player. However, by definition, the Warburg effect takes place even in the presence of adequate oxygen supply, and the gradient inversion at the very beginning of cancerization occurs before any hypoxia develops. Both metabolic mechanisms form part of the adaptation of malignant cells to high proliferation, which creates harsh conditions, namely hypoxia and the increased amounts of protons. While hypoxia is handled through a form of metabolism that does not need oxygen, aerobic glycolysis, the excess of proton production is dealt with through increased proton extrusion from the cell. An excess of intracellular protons remaining inside the cell would be toxic and jeopardize the cell’s survival.

After thirty years of research on the pH paradigm, authors concur that it represents a powerful driver of cancer initiation and progression [5,25].

3. The pHtome and How the Paradigm Appears
pHtome is a neologism that gathers in one word all the cellular and extracellular elements that participate in creating the pH paradigm. It comprises voltage-gated channels, ion exchangers, transporters, water channels, enzymes, buffers, transcription factors, specialized areas of the cell membrane, and probably some as yet unknown proteins [26]. At least ten of all the participants in the pHtome have been identified as the paradigm’s main culprits, but this does not mean that there are no others. The pHtome participants have overlapping functions, thus inhibiting one of them has no lasting effects on the pH paradigm, since the others can easily compensate for it. Inhibition of many, on the other hand, is more difficult for the tumor to overcome. This is the theoretical framework on which the treatment scheme shown below is based.

Another important issue is that these participants coordinate among themselves to some degree. Possibly the main coordinators are the pH itself, growth factors, hypoxia, metabolic pathways, transcription factors such as hypoxia-inducible factors (HIFs) and Sp1 (specificity protein 1), and some specific genes such as Myc. We say possible coordinators, because a master coordinator or regulator has not been clearly identified beyond pH itself. The main participants of the pHtome are:(1) Sodium-hydrogen exchangers1 and 3 (NHE1 and NHE3)

(2) Voltage-gated sodium channels (VGSCs)

(3) Membrane carbonic anhydrases 9 and 12 (CAIX and CAXII)

(4) Intracellular carbonic anhydrases

(5) Sodium bicarbonate cotransporter-1 (NBC1)

(6) Vacuolar ATPase proton pumps (PPs)

(7) Monocarboxylate transporters 1 and 4 (MCT1 and MCT4)

(8) Na+/K+/2Cl− cotransporter (NKCC1)

(9) Cl−/CO3H− exchanger

(10) Specificity protein 1 (Sp1) transcription factor

(11) Lactate and the lactate shuttle

(12) Lactate dehydrogenase

(13) Growth factors

(14) CO2

(15) Aquaporins (Figure 1).



The main players in the pH paradigm: (1) Sodium-hydrogen exchangers 1 and 3 (NHE1 and NHE3)

(2) Voltage-gated sodium channels (VGSCs) (Figure 1)



In the 1970s, it was discovered that sea urchin eggs underwent a significant increase of pHi immediately after fertilization as a necessary condition for proliferation [27,28,29,30]. Furthermore, intracellular alkalinization can be considered a signal for proliferation [31]. This pHi increase, which was also found in other species, was the result of an enhanced proton extrusion and sodium import. In 1984, Pouyssegur et al. [32] showed the critical role of NHE1 in intracellular pH regulation and the role of this regulation in cellular growth and proliferation [33]. The relationship between proliferation and migration, in cancer and NHE1, was further confirmed by other authors as well [34,35,36,37,38,39,40,41]. Furthermore, NHE1 activity also plays a role in tumor cells’ escape to the cytotoxic effects of chemotherapy [42]. Growth factors exert control on NHE1 [43]. It is probably through their signaling that the pH threshold that activates NHE1 is increased. This means that NHE1 will become active with a higher intracellular pH Figure 2 and Figure 3).

(3) Membrane carbonic anhydrases 9 and 12 (CAIX and CAXII)

(4) Sodium bicarbonate cotransporter1 (NBC1) (Figure 2)

There is ample evidence showing the pro-tumoral activity of carbonic anhydrases, in particular the membrane CAs, 9 and 12 (CAIX and CAXII) [53,54,55,56,57,58,59], but also non-membrane CAIV [60], CAIII [61], and CAII.

CAs catalyze the reversible hydration of CO2 to form carbonic acid, which is immediately ionized to bicarbonate and a proton (CO2 + H2O → CO3H+ + H+) (Figure 4).

While the proton thus released contributes to extracellular acidity, the bicarbonate is reintroduced into the cell by NBC1, contributing to intracellular alkalinity.

Overexpression of membrane CAs is classically considered a sign of tumor hypoxia [62,63], however, there are tumors, such as prostate cancer, that in spite of being hypoxic, do not overexpress CAIX or CAXII [64]. 

CAs work “in tandem” with NBC1 [65] that introduces the bicarbonate produced by the CAs into the cell. The “coordinator” of this tandem work is in the hands of membrane carbonic anhydrases that regulate the amount of bicarbonate produced and at the same time, participate in the bicarbonate transport process [66,67].

Therefore, NBC1 also plays pro-tumoral roles through its association with membrane CAs or even independently [68]. Intracellular CAs also participate as facilitators of NBC1 bicarbonate transport in normal heart tissue [69] and, we suppose, in cancer as well. The exact mechanism has not been fully clarified (Figure 4). 

(5) Vacuolar ATPase proton pumps (PPs)

PPs extrude protons from the cell with energy consumption, through two mechanisms: directly or into endosomes (Figure 5). Decreasing intracellular protons increases pHi, while increased extrusion decreases pHe.

There are many publications in the medical literature showing that proton pumps play an essential role in the pH paradigm [71,72,73], and PPIs (PP inhibitors) can be a useful tool in cancer treatment [74,75,76]. There are also some controversial population studies reporting that chronic use of PPIs does not decrease cancer risk and, on the contrary, increases gastric cancer risk [77,78,79,80]. Without entering in this controversy which is based on populations that had Helicobacter pylori infection, and is therefore biased, it is necessary to establish that:(1) V-ATPase proton pumps play an important role in the pH paradigm.

(2) They represent the main acidification machinery of endosomes whose content is released to the extracellular space or migrates from the cell as exosomes.

(3) Therefore, using PP inhibitors (PPIs) as part of a pH-centered therapy responds to this logic.

(4) PPIs may not prevent cancer and they may even increase the risk of gastric cancer, as the new research suggests, but the patients who receive PPIs as part of a cancer treatment already have cancer.

(5) The survival time of most of these patients is usually shorter than the prolonged time PPIs administration requires for increasing the risk of a second cancer.



Therefore, our conclusion is that a possible risk increase using PPIs is inconsequential for our purposes.

(6) Monocarboxylate transporters 1 and 4 (MCT1 and MCT4)

(7) Lactate (Figure 6)

For a review of both items, read the studies by Payen et al. [81] and Panisova et al. [82]. 

Monocarboxylate 4 is the main isoform for lactate transport leaving the cell. Monocarboxylate 1 introduces lactate into oxidative cancer cells in the lactate shuttle process. MCT4 and MCT1 are overexpressed in many malignancies such as non-small cell lung [83], breast [84,85], colorectal [86], gastric [87], clear cell renal carcinoma [88], and prostate [89], among many others.

The importance of MCTs is rooted in the high lactate production of almost all malignancies and thus the need to extrude it from the cell avoiding an intracellular lactic acidosis that would induce apoptosis. 

Lactate extruded from cells has been identified as a pro-tumoral factor through diverse mechanisms [90,91]. Inhibition of lactate production has shown anti-tumoral effects [92,93].

Some of lactate’s effects are related to its ability to increase extracellular acidity, however, there are pro-tumoral effects independent of the pH paradigm. 

On a theoretical basis, we have proposed increasing lactate production with metformin and at the same time, decreasing lactate extrusion by MCT4 inhibition. This situation would increase intracellular lactate with toxic effects on the malignant cell [94]. This idea has been experimentally confirmed at the cellular level [95,96,97] but has not been tested in the clinical setting. Benjamin et al. [95] used syrosingopine to achieve MCTs inhibition.

Syrosingopine is a rauwolfia derivative with antihypertensive properties [98] which has been used in clinical practice since the early 1960s [99,100,101]. It has been replaced by new antihypertensive drugs. However, syrosingopine has an interesting effect: MCT1 and MCT4 inhibition [102,103,104].

According to the authors mentioned above, syrosingopine exerts its anti-tumoral effects by depleting ATP. We think that the main action of syrosingopine is through intracellular lactic acidosis that inhibits the glycolytic flux. When used in association with metformin, this intracellular lactic acidosis is further enhanced, resulting in apoptosis.

(8) Na+/K+/2Cl− cotransporter (NKCC1)

(9) Cl/CO3H− exchanger (SLC4A8) (Figure 5)

NKCC1 is a symporter that incorporates Na+, K+, and Cl− to the cell. On the other hand, the chloride/bicarbonate exchanger is an antiporter that extrudes Cl− and imports bicarbonate. The exchanger works in close association with CAII. Some authors consider NKCC1 expression as a potential pro-tumoral agent [105,106,107,108]. NKCC1 indirectly participates in cytoplasmic alkalinization through its association with the Cl−/CO3H− exchanger [109]. Figure 7 explains the complementary mechanism of action of these two membrane proteins and cytoplasmic carbonic anhydrase II (CAII) [110,111]. The interaction between chloride/bicarbonate exchanger and CAII is so important that by inhibiting CAII with acetazolamide, the level of ion transport through the membrane decreases significantly [112].

The diuretic bumetanide inhibits NKCC1 [123,124]. However, we have not used it with patients receiving quercetin (quercetin activates NKCC1). Topiramate, which is part of the treatment scheme, seems to be able to downregulate NKCC1 [125], thus compensating quercetin’s effects on this transporter.

(10) Sp1 transcription factor

This transcription factor is involved in the regulation of many genes. Interestingly, it induces/enhances the expression of many of the participants of the pHtome, namely CAIX [126,127], NHE1 [128], NHE2 [129], NHE3 [130], NBC1 [131], and some proton pumps such as H-K-ATPase [132]. Furthermore, Sp1 transcription activity is pH-dependent [133]: low intracellular pH increases Sp1 DNA binding and its interaction with TATA binding protein. In summary, Sp1 is a housekeeper that prevents low pHi. Therefore, it is a player in the pH paradigm. Independently of its effects on the pH paradigm, there is abundant evidence showing the pro-tumoral activity of Sp1 [134,135,136,137].

The best known Sp1 inhibitors are tolfenamic acid [138,139] and mithramycin [140]. The pain-reliever tolfenamic acid has been safely used for the treatment of cephalea for many years, but now it is only available for veterinary use. Interestingly tolfenamic acid not only downregulates Sp1 but also has many other anti-cancer effects [141,142,143,144,145,146,147,148,149,150,151].

This short list does not mean that there are no other channels, transporters, and proteins involved, such as calcium and potassium channels, aquaporins, etc., however it shows that these above-mentioned ten are well known, have been extensively investigated, and seem to have a primary and essential role in the paradigm. Furthermore, inhibition of any of the first seven significantly modifies intra- and/or extracellular pH. However, their functions overlap and usually inhibiting just one is not sufficient.

For a long time, excessive lactate produced by increased glycolytic flux was considered as the main avenue towards extracellular acidity (recently reviewed by Parks et al. [12]). However, experimental evidence with tumors artificially engineered to become low lactate producers showed that the paradigm was still present even without this metabolite.

Our limited clinical experience has shown that targeting only one pHtome participant has little effects. We have to address at least three of them, with NHE1 being the main target.

4. Clinical Approach
Recognition of this eleventh hallmark of cancer raises many questions in the mind of the practicing physician:(1) Is it important?

(2) Does it require treatment?

(3) Can it be treated?

(4) How to treat it?



(1) Is it Important?

Laboratory experiments have shown that reversing the inverted pH gradient entails great difficulties for tumor initiation [5,152], growth [153], progression [154], invasion [155], metastasis [156], and relapse [157]. The pH paradigm decreases cellular immune defenses against the tumor [158,159,160,161] and the effects of some chemotherapeutic drugs [162,163]. It also plays a role in intercellular communication through exosomes [164]. Thus, the answer is yes, it is important, because it has a fundamental role in promoting almost all the other cancer hallmarks. Furthermore, migration, invasion, and metastasis become very difficult, albeit not impossible, when the inverted gradient is returned to normality.

(2) Does it Require Treatment?

Many chemotherapeutic and targeted treatments modify the paradigm through their cytotoxic-apoptotic effects on the tumor mass. However, remaining malignant and dormant cells will reproduce the cellular and microenvironmental pH they need. It is here that targeting the paradigm may achieve better results. There is another situation in which extracellular acidity needs to be modified for a successful therapeutic result: weak basic chemotherapeutic drugs.

Interestingly, the therapeutic reversion of the inverted gradient, with no other anti-tumoral treatment, may achieve promising results, as we shall see in case Number 1.

(3) Can it be Treated?

The pH paradigm is the result of the dysregulated activity of many or all the participants of the pHtome. There are inhibitors that can partially or totally block the action of five of them. These inhibitors already exist, and many are in clinical use for other diseases. In general, they lack toxicity, or at the most, toxicity is minimal. There is no available inhibitor of NBC1 in the clinical setting. Lactate production can be decreased by inhibiting lactate dehydrogenase (LDH), however there is no effective inhibitor for bedside use. Our analysis and treatment scheme will be based exclusively on existing drugs that are suitable for treating patients.

(4) How to Treat?

The main culprit of the pH gradient inversion is NHE1. Therefore, this is the first pHtome member to be considered. However, it is necessary to inhibit many members in order to achieve anti-tumoral effects.

5. NHE1 and NHE3 Inhibition
Amiloride, a well-known potassium-saving diuretic that has been in clinical use for over fifty years, is an inhibitor of NHE1 and a mild NHE3 inhibitor [165,166]. Both isoforms of NHE are important for pHi regulation, however there is evidence that NHE1 is the main regulator [167]. There is also evidence showing that NHE1 inhibition by amiloride has anti-tumoral effects [168,169,170,171,172], that are not limited to NHE1 inhibition, but also inhibits uPA (urokinase plasminogen activator) [173,174]. Amiloride’s anti-uPA effects seem to be of particular importance in prostate cancer where uPA’s overexpression plays an important role [175].

The usual 5 mg dose used in heart failure patients is insufficient to achieve an important inhibition of NHE1 as required in cancer treatment. A 20 mg daily dose showed minimal side effects due to hyperkalemia, which could be solved by simultaneous use of diuretics such as furosemide or hydrochlorothiazide.

Cariporide is a more potent NHE1 inhibitor compared with amiloride, although not FDA (Food and Drug Administration USA)-approved [176]. However, this drug has been tested in more than 10,000 patients in the cardiologic context (Guardian Trial) and in spite of not reaching the desired endpoints, the drug proved to be non-toxic and very well tolerated by patients [177,178,179]. In 2001, in a Doctoral Dissertation, Wong [180] was the first to call attention to cariporide as a possible drug for cancer treatment. In 2007, Sario et al. [181] found that cariporide reduced migration and proliferation of cholangiocarcinoma cells. Many reports since then have shown the anti-cancer abilities of cariporide [182,183,184,185] that confirmed these findings. In 2013, Harguindey et al. [186] suggested cariporide for cancer treatment. Subsequent publications further confirmed cariporide’s effects as an anti-cancer drug [187,188,189] and its ability to produce significant intracellular acidification in malignant cells [190]. However, cariporide is still waiting to be called into active service. Furthermore, there are no registered clinical trials for cariporide in cancer.

Other NHE1 inhibitors: There are amiloride and cariporide derivatives that are more potent than amiloride and have also shown anti-cancer properties. Not one has been approved for clinical use.

Therefore, amiloride is the only available pharmaceutical, approved by the FDA as a diuretic and available on the market.

6. Voltage Gated Sodium Channels (VGSCs) Inhibition
Most anti-epileptic drugs in clinical use, including phenytoin [191,192,193], carbamazepine [194,195,196,197], lamotrigine [198], topiramate [199,200,201,202], and many others, inhibit VGSCs and show different degrees of anti-tumoral effects (for a review see Koltai [203]). From a long list of VGSC inhibitors, we have chosen topiramate because it has a quadruple action against tumors:(1) It is a VGSC inhibitor [204]

(2) Topiramate is a potent acidifier of the intracellular milieu [205]

(3) It inhibits mainly CAII, and to a lesser degree CAIX and CAXII [206,207]

(4) It inhibits aquaporin 1 [201], aquaporin 4 [208], and aquaporin 5 [209]. Aquaporins are also participants in tumor development [210,211,212,213,214] and the pH paradigm [215,216,217]. This seems to be of particular importance in glioblastoma [218,219].



The importance of CAII inhibition by topiramate is that it has a triple effect:(a) It impedes NHE1 enhancing activation by CAII [220,221]

(b) It impedes intracellular recycling of bicarbonate. Both actions of topiramate reinforce its cell acidifying effects

(c) It blocks other pro-tumoral effects of CAII [222,223,224,225,226,227].



The starting dose is 50 mg with weekly increments of 50 mg until achieving 200 mg daily.

NHE1 and VGSCs work together in a pro-tumoral manner, but they also have independent actions. Based on this logic, we think that NHE1 and VGSCs should be addressed simultaneously. The amiloride and topiramate association would be suitable for this purpose.

7. Carbonic Anhydrase (CA) Inhibition
Acetazolamide: It was the characterization of carbonic anhydrase in 1933 [228] which was followed by the discovery that sulfanilamide, the active metabolite of the sulfonamide Prontosil, inhibited CA, which led to increased natriuresis and the excretion of water [229]. Sulfanilamide gave rise to better CAs, such as acetazolamide. Diamox, the brand name of acetazolamide, was originally used for congestive heart failure and glaucoma. Nowadays, it is used for intracranial hypertension, glaucoma, altitude sickness, and Meniere’s disease. Toxicity is very low, however side effects are abundant, such as tinnitus, paresthesia, loss of appetite, vomiting, fatigue, and sleepiness. Administration of high doses of acetazolamide for long periods is not well-tolerated by patients. Therefore, Diamox should be used in the treatment of the pH paradigm only for a short time or at small doses. Some tumors, such as prostate cancer, do not show overexpression of membrane CAs, thus we have doubts about inhibiting CA in this case.

There is very active research for specific CA inhibitors to replace the unspecific acetazolamide. However, inhibiting membrane CAs is not enough to reverse the inverted pH gradient; some cytoplasmic CAs, such as CAII [222,230,231,232], CAIV [233], and other CAs [234], should be targeted too. Therefore, we believe that acetazolamide is adequate for this purpose.

8. V-ATPase Proton Pump Inhibition (PPI)
V-ATPase proton pump inhibition has been shown to have the ability to reduce tumor growth and proliferation [235,236]. Ferrari et al. [237] showed that PPIs increased chemosensitization in osteosarcoma patients. Wang et al. [238] reported similar findings in breast cancer patients.

There is an abundance of PPIs in clinical practice, including omeprazole, esomeprazole, pantoprazole, lansoprazole, etc., and they are all used for the treatment of gastrointestinal hyperacidity. We selected lansoprazole due to some anti-tumoral advantages such as suppression of tumor necrosis factor α (TNFα), NF-kB activity, phosphorylation of ERK [239], decreased adhesion of cancer cells to the matrix [240], synergy with metronomic chemotherapy [241], and synergy with carbonic acid inhibitors [242]. There is also evidence of pro-apoptotic activity in cancer cells [243,244], and of fatty acid synthase inhibition [245].

9. MCT Inhibitors
There are no FDA-approved drugs with potent MCT inhibitor abilities. However, there is a commercially available nutraceutical that can partially inhibit MCT: quercetin. Quercetin is a natural flavonoid that has shown preventive [246] and therapeutic effects in cancer:(1) Inhibiting cell cycle progression [247,248],

(2) Inducing apoptosis limited to cancer cells [249],

(3) Interfering with reactive oxygen species (ROS) metabolism [250],

(4) Inhibiting the androgen receptor in prostate cancer [251],

(5) Targeting cancer stem cells [252],

(6) Downregulating mutant p53 [253] and metalloproteinases 2 and 9 [254],

(7) Inhibiting p21-RAS expression [255],

(8) Decreasing glycogen synthesis [256],

(9) Antagonizing inflammation [257],

(10) Inhibiting Hsp 27 [258],

(11) Decreasing cMyc and PI3K/Akt signaling [259],

(12) Decreasing lipogenesis [260],

(13) Amid other anti-cancer effects [261,262].



Many of these actions are probably independent of MCT inhibition. For the purpose of the pH-centered treatment, quercetin is able to interfere with lactate export, thus decreasing intracellular pH [263,264]. This is achieved through MCT inhibition [265,266]. Decreased lactate transport diminishes fermentative glycolysis as well [267,268]. However, there is evidence showing that quercetin might increase NHE3 activation [269]. We presume that this is due to the intracellular acidification generated by quercetin and further confirms the need for simultaneous inhibition of the exchanger with amiloride when quercetin is used.

Additionally, quercetin activates the Na+/K+/2Cl−-cotransporter (NKCC1) [270], increasing intracellular Cl−. However, electroneutrality is maintained because it simultaneously imports Na+ and K+. The cytosolic acidification induced by quercetin is mainly due to MCT inhibition and lactate accumulation, and not by NKCC1 activation. There is also evidence that quercetin is able to reduce mitochondrial energy production [271]. However, this last effect requires concentrations that are difficult to achieve in the clinical setting.

One big advantage of quercetin is that neither toxicity [272,273] nor genotoxicity [274] were reported, even with very high doses [275]. Renal toxicity may ensue with doses above 1000 mg per square meter when the intravenous route is used [276]. Absorption of quercetin is not so poor as some authors have stated. The range of absorption is between 17% and 50% with an oral intake in humans. The wide range depends on the attached chemical, being the highest for quercetin glycosides and the lowest for quercetin rutinoside, while quercetin aglycone (the product found on the market) is approximately 25% [277]. The mean time to achieve maximum concentration was shorter for quercetin aglycone than the rutinoside form [278]. A dose of 330 μMoles reached a peak concentration of 5 μMoles/liter in plasma forty minutes after ingestion [279]. A single ingestion of 300 mg of quercetin achieved a plasma concentration of 9.72 μMoles [280]. A concentration of 1 μMol causes a 23% reduction of TNFα production in healthy individuals [281] and prolonged administration of quercetin significantly increased plasma concentration [282]. Therefore, we must conclude that oral administration of quercetin has an acceptable absorption and can achieve a concentration that is able to produce biologic effects.

Daily, 600 to 1000 mgs of oral quercetin is a safe dose.

Statins were proposed as MCT4 inhibitors [283,284,285]. Precisely one of the side effects of chronic statin use is its actions on muscle cells characterized by cramps due to lactic acid accumulation inside the myocytes [286].

There is no published research on the association of statins with quercetin to induce MCT inhibition. Thus, we do not know if there is synergy. Published data on this association has not investigated the issue [287]. In spite of this gap in our knowledge, we used both drugs in association in order to inhibit the MCT system.

10. The Role of Metformin in the pH Paradigm Treatment
The “metformin dream” began in 2005, when a large population study of diabetic patients showed that those taking metformin had a lower risk for cancer [288,289,290]. This “dream” consists of many “beliefs” about this simple and old drug, e.g., that it can:(1) Improve the results of cancer treatment,

(2) Reduce the risk of cancer in non-diabetics,

(3) Be included in all cancer protocols.



These beliefs have not been validated by strong clinical data. In the first place, metformin reduces the risk of cancer in diabetic patients who already have an increased risk for cancer. That result cannot be extrapolated to non-diabetic populations. Many of these supposed metformin risk reduction studies are biased and have many confounding factors [291,292] because the comparison is made with populations receiving the pro-tumoral insulin or some other anti-diabetic compound.

Adding metformin to usual cancer therapy has not shown the expected results.

However, correctly used metformin does have a place in cancer treatment, although not in risk reduction of non-diabetics. The mechanisms that have been classically postulated for metformin’s anti-tumoral action are not the most important (for the postulated classical mechanisms read Kasznicky et al. [293], Rena et al. [294], and Vancura et al. [295]). The real anti-tumoral action of metformin arises from its main mechanism of action: inhibition of Complex I of the mitochondrial electron respiratory chain [296,297,298,299,300,301,302,303]. This inhibition downregulates oxidative phosphorylation and increases glucose fermentation to lactate [304,305,306]. Lactate in the cytoplasm decreases pHi [307]. Therefore, metformin is a cytoplasmic acidifier. The more glucose is metabolized, the more lactate is produced in presence of metformin. But the lactate is swiftly exported by MCT4. Metformin alone is inefficient to significantly decrease pHi. Metformin in high doses (3 to 4 g daily) associated with MCT inhibitors is an efficient combination to reverse the pH paradigm. This has not been tested in vivo.

11. The Bedside Treatment Scheme
The treatment is based on the inhibition of at least three of the elements that create the pH inversion as follows:(a) NHE1 is inhibited with amiloride.

(b) V-ATPase proton pumps are treated with lansoprazole.

(c) VGSCs, CA, and aquaporin 1 are targeted with topiramate.

(d) Additionally, stronger inhibition of CAs can be achieved with acetazolamide. However, the tolerance for high doses of acetazolamide for long periods is very low in many patients. The main use of acetazolamide in the scheme is in the first month of treatment when topiramate has to be slowly increased. Once a full dose of topiramate is achieved, it is convenient to reduce the acetazolamide dosage. If patient tolerance is good, acetazolamide is an efficient non-specific CA inhibitor.

(e) Sp1 transcription that induces HIF1 stabilization, NHE1, and CAs expressions can be inhibited with celecoxib, a COX2 inhibitor. Actually, the best drug for targeting Sp1 is tolfenamic acid (FDA-approved for human use), but it is not available in many countries.

(f) MCTs are inhibited with high doses of the non-toxic nutraceutical quercetin in association with simvastatin or other statins. In a few cases, we used metformin as part of the scheme, but lately it has been eliminated due to poor patient tolerance to high doses.



The simultaneous targeting of at least three of the main players of the pHtome effectively decreases intracellular pH, thus reversing the paradigm [308].

12. Side Effects of the Treatment
The patients’ usual complaints are constipation, asthenia, paresthesias, dysgeusia, and orthostatic hypotension. Constipation is due to metformin and statins and responds adequately to symptomatic treatment. Paresthesias, asthenia, and dysgeusia are common effects of acetazolamide at high doses. Dose reduction decreases the symptoms but usually not completely. In some cases, acetazolamide was reduced to low doses (250 mg a day) with better tolerance. Topiramate is able to replace acetazolamide as a carbonic anhydrase inhibitor, however, acetazolamide is still needed for adequate inhibition of CAIX and CAXII. Celecoxib also has CA inhibitor abilities.

Interestingly, in patients that received the treatment for very long periods (Case Number 1), side effects subsided after a year. Orthostatic hypotension is also a common complaint. Patients should be advised to stand up slowly in order to avoid this problem. They should be instructed to have a high fluid intake to avoid kidney stone generation.

In general, the treatment was well-tolerated by all the patients. Dose adjustment was necessary in some cases.

13. Pet Cancer Treated with pH-Centered Schemes
Spontaneously occurring tumors in small pets—mainly cats and dogs—are closely related to human cancer and can be considered a good model of human cancer [309].

Pets, and dogs in particular, have high incidence of spontaneous cancers, and their molecular mechanisms are quite similar to those found in humans. Considering that they have a shorter life span and cancer progression time and taking into account some relative differences [310], these animal studies may be useful as a proof of concept. The group headed by Fais and Spugnini [311,312] found that the proton pump inhibitor lansoprazole was able to reverse drug resistance in 67% of dogs with spontaneous cancers, achieving complete or partial remission. Combining metronomic chemotherapy with high-dose lansoprazole, the results further improved with 75% of complete, partial, or stable disease response. Our own experience showed similar results with a full pH-centered scheme associated with metronomic chemotherapy [313].

14. Results of pH-Centered Treatments in Humans
Eleven patients with different, very advanced tumors, were treated on a compassionate basis with part or the total scheme. Ten patients were under palliative care and were not receiving chemo- or radiotherapy at the time they started the treatment. They were all heavily treated previously, and the disease was in progression with multidrug resistance.

Six patients did not show any improvement with the scheme. In this group of non-responders, there was one with relapsing glioblastoma, two patients with pancreatic cancer, one case of ovarian metastatic cancer, one patient with colon cancer, and one with gastric adenocarcinoma.

Five patients showed stable disease for prolonged periods:

One patient with metastatic renal cell carcinoma (Case Number 1) achieved stable disease for the last 68 months and continues without signs of progression up to now.

One patient with relapsing gastric lymphoma has not shown signs of progression after 48 months (Case Number 2).

Of the two patients with prostate carcinoma, one showed stable disease for 19 months before progression reappeared (Case Number 4). The other patient has been stable for 48 months (Case Number 3). In Case Number 4, the patient was simultaneously treated with a metronomic anti-angiogenic scheme based on daily oral cyclophosphamide and fenofibrate. Case Number 5, a patient with wide-spread metastatic melanoma, achieved stable disease for 11 weeks.

All the patients signed an informed consent after a detailed explanation of the treatment. This consent was co-signed by two witnesses, being at least one of them a family member or close friend of the patient. 

No authority permissions were required for the treatment because all the drugs and nutraceuticals used, were approved by the National Drug and Medical Technology Administration of Argentina (ANMAT) and no experimental or non-approved drugs were administered to the patients.

15. Human Case Presentation
Case 1: In 2002, an asymptomatic 43-year-old male was diagnosed with a right renal cell carcinoma by chance during an abdominal X-ray checkup. A radical right nephrectomy was performed, and a 3.5 cm diameter clear cell renal cell carcinoma was found and removed. There were no regional or distant metastases at the time.

Three years later, three nodular metastases of less than one cm appeared in the right lung and a mediastinal metastasis was detected shortly thereafter. All the metastases were surgically removed. The patient remained asymptomatic for two years, when two spine and one iliac bone metastases appeared. He received radiotherapy and seven months of treatment with daily 25 mg of sunitinib (2013). He achieved stable disease but developed severe heart failure and hypertension. In 2014, he showed a rib metastasis and two small left lung metastases (less than 1 cm each). In 2014, he started with the pH gradient inversion treatment and cardiologic drugs. The treatment consisted of lansoprazole 180 mg, amiloride-base diuretics (5 mg amiloride plus 25 mg hydrochlorotiazide three times a day), acetazolamide 250 mg, celecoxib 400 mg, quercetin 600 mg, and silymarin compound. The acetazolamide was poorly tolerated, and it was replaced with topiramate 200 mg (started with 50 mg and increased 50 mg every ten days). The patient achieved stable disease. The metastases did not disappear, but they did not grow any further, as his last control in March 2020 showed. Tolerance for the treatment was and is excellent, with the main adverse effects being constipation, slight hypotension, and minor asthenia. Constipation was treated symptomatically. During the six years he received the treatment, he was able to return to a normal lifestyle, including a divorce, a remarriage, and having a baby.

The scheme used in Case 1 is shown in Table 1.

Figure 8 and Figure 9 show bone surveys of the patient.

The patient is now 61 years old and has stable disease which has not evolved over the past 6 years.

Case 2: An 84-year-old woman presented a gastric lymphoma in 2014. She was treated only with omeprazole and rituximab. No other drugs were used due to the patient’s poor conditions. Complete response was achieved for four years. In 2018, an important gastric bleeding led to a gastroscopy that showed tumor relapse. The patient and the family rejected any aggressive treatment or chemotherapy, thus, a pH-centered therapy (lansoprazole, quercetin, metformin, amiloride, and silibinin in similar doses as in Case Number 1) was started. The patient’s physical conditions improved, and a control gastroscopy performed in 2020 showed the presence of lymphoma cells in the biopsy without evidence of tumor growth. Computed axial tomography showed no other organ involvement. Follow-up of 26 months.

Case 3: This 66-year-old patient is the exception in the sense that he was not a terminal case. The patient had a localized prostate cancer with no detectable metastasis. He was treated with radiotherapy and refused hormonal or chemotherapy treatments. Two years after the radiotherapy, persistent and progressive elevation of PSA ensued. No metastases were detected. The patient was started with the pH-centered treatment and PSA progressively diminished, achieving normal levels after one year. Six years after the initial diagnosis, the patient shows no metastasis and PSA is within normal limits.

Case 4: A 59-year-old patient was started on the pH-centered treatment in association with metronomic chemotherapy in 2010 for a metastatic castration-resistant prostate cancer after progression with radical prostatectomy, hormonotherapy, and chemotherapy. Bone metastases, a total of 12 (ribs, spine, pelvis, and femur), were treated with radiotherapy. The pH-centered treatment (lansoprazole, acetazolamide, silymarin, and riluzole) with metronomic chemotherapy (cyclophosphamide, celecoxib, and bazedoxifene) was initiated when the patient was on palliative care. There were neither new metastases nor growth of the existing ones for 19 months. After this period, two new bone metastases appeared and there was no further response to treatment.

Case 5: A 29-year-old male was started on a pH-centered metronomic chemotherapy scheme for the treatment of metastatic melanoma, with pulmonary, liver, spleen, adrenal, lymph nodes, and brain metastases, unresponsive to immune checkpoint and BRAF inhibitors. There were more than 20 metastases in the liver and lungs. There were two small brain metastases without cranial hypertension syndrome. The patient showed stable disease for eleven weeks, after which new metastases appeared.

16. Discussion
To the best of our knowledge, this is the first publication of the results obtained with a “cocktail” of proton extruder inhibitors in patients with very advanced stages of cancer.

There are two shared issues in the four cases presented here (Case Number 3 is excluded):(1) Above average survival.

(2) Stable disease achieved with pH gradient inversion treatment.



Of course, there have been blatant failures too: the other six cases. However, all six failures occurred with patients almost in extremis (all of them passed away within three months). Therefore, an important question remains unanswered: would the results be improved with an earlier pH-centered treatment? Only further research can answer that.

pH-centered treatments also achieved stable disease in spontaneous dog and cat cancers.

This limited clinical experience shows that in some cases, pH treatments can achieve stable disease and decrease metastasis, although no complete or partial remission is within its abilities. Case Number 1 is a good example that with stable disease, it is possible to live a normal and good-quality life. Case Number 5 only shows a short period of stable disease, but this was brought about by a pH-centered treatment after all known therapeutic measures failed and in a very advanced stage of the disease, where remissions or stabilization are unusual.

The small number of cases, the diversity of the tumors, and the presence of confounding factors, does not permit the establishment of a proof of concept. However, a scheme of treatment was proposed which is rationally based on translational and pharmacological fundamentals. The concept of a proton extruder inhibitor cocktail as proposed by many authors has been materialized here with repurposed drugs and nutraceuticals. This is only a first step. Improving the cocktail and performing clinical trials should follow.

Quiescence of cancer cells is a major problem in tumor targeting because these cells are not responsive to classical therapies [334]. This situation is frequently a consequence of chemo- or radiotherapy [335]. Interestingly, quiescent cells have a low intracellular pH and low expression of NHE1 [336]. Our interpretation of the clinical results of the pH-centered treatments is that it is able to induce a state of quiescence in cancer cells (stable disease) rather than apoptosis (remission). The unknown issue is how to prolong this quiescence.

17. Future Perspectives
For bioethical reasons, we were constrained to use only FDA-approved drugs or nutraceuticals, even though they were approved for other uses than cancer. These important limitations meant that we had to leave aside some better drugs. For example, amiloride is a weak NHE1 inhibitor in the clinically achievable concentrations. Cariporide is significantly more potent, and in spite of its low toxicity, it is not an approved drug. Another example is that of MCTs inhibition with quercetin. It is a nutraceutical, and it is available over the counter on the market. On the other hand, the old anti-hypertensive drug syrosingopine is no longer available for clinical use. Something similar occurs with tolfenamic acid, probably the best non-toxic, and well-known inhibitor of Sp1 and Sp3, which is only available for veterinarian use.

Improving the pHtome inhibition with new and old drugs may perhaps achieve better results with the pH-centered treatment. Hopefully, some old drugs may make a comeback, namely tolfenamic acid and syrosingopine. Hopefully, also, maybe in the future, quercetin will receive the attention it deserves, not as a nutraceutical but as a drug with clear and confirmed anti-cancer properties.

The second issue is that no clinical trials are being conducted on a pH-centered scheme. If the future brings a well-planned clinical trial and awakens awareness about this approach, the gap between the experimental laboratory and bedside therapy may narrow.

18. Conclusions
The last 30 years have witnessed growing interest and research on the tumor microenvironment. This research has shown that tumor acidity, as originally conceived by Warburg and his contemporaries as a by-product of excessive glycolysis and lactate production, was the tree hiding in the forest. The investigation of the forest, rather than the tree, showed a complex world in which intracellular alkalinization, pH gradient inversion, the mechanisms involved, and the consequences thus produced became a whole new chapter in cancer biology. However, this knowledge has not reached bedside medicine. After briefly reviewing the pathogenesis of the pH paradigm, this contribution shows some practical ways of addressing the issue outside the laboratory. What we have learned from basic research and from a very limited clinical experience is that:(1) pH gradient inversion, known as the pH paradigm, is a hallmark of cancer.

(2) This hallmark is not the consequence of metabolic changes, but a parallel process that may even precede the metabolic switch.

(3) However, it is not independent from the metabolic switch. The latter has the ability to further increase the pH gradient inversion and at the same time, requires increased intracellular pH to enhance the activity of some glycolytic enzymes.

(4) Metabolic switch and pH gradient inversion let the cell acquire proliferative and growth advantages.

(5) Reversing the pH paradigm decreases growth, proliferation, and tumor progression in the experimental laboratory level and also at the bedside.

(6) Reversal of the pH paradigm can be achieved with existing drugs by repurposing them.

(7) The aim of the treatment is based on the simultaneous inhibition of many (at least three) of the components of the pHtome.

(8) It is insufficient to block one or two proton extruders. As many as possible proton extrusion mechanisms need to be inhibited in order to get significant results.

(9) NHE1 should always be one of the targets in any pH-centered scheme.

(10) The treatment scheme hereby shown is only an example that can be improved with better inhibitors of the pHtome.

(11) The cases reported in this paper do not represent a proof of concept. Many confounding factors could not be ruled out and the population was too small to achieve statistical significance.

(12) There were no complete or partial remissions. However, stable disease for an extended period is an achievable result.

(13) Resistance to pH-centered treatments may be present from the beginning (failed cases) or may develop at variable times, or almost never (Cases 1 and 2).

(14) How and why resistance to pH-centered treatments develops has not been investigated as yet. Tumor heterogeneity and flexibility to changes is probably at the roots of resistance.

(15)  pH-centeredcancer treatment deserves well-planned large-population studies, with reliable statistics and long follow-up.



We hope this article will encourage fellow colleagues to follow the research and mainly to consider pH-centered treatments worthy of serious clinical trials. Until the results of these trials are available, “the defense rests”.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Funding
This research received no external funding.

Conflicts of Interest
The author declares no conflict of interests.

Figure 1 Mechanisms of action of the pHtome participants.

Figure 2 Mechanism of pH threshold modification of NHE1.

Figure 3 Mechanism of action of NHE1 and VGSCs. NHE1 is an exchanger that imports sodium ions while exporting protons (hydrogen ions). This proton removal from the cell increases intracellular pH while it increases in the extracellular space. VGSCs import sodium ions but do not export protons. Among their other effects, the importance of VGSCs lies in the fact that they activate NHE1 [44]. Activating NHE1 means that it “starts working” at a higher intracellular pH. Under normal conditions, NHE1 has a pHi threshold and becomes active when pHi goes below it. VGSCs increase the threshold, leading to NHE activation even under higher intracellular pH. There is a well-established relationship among growth factors, NHE1, intracellular increase of pH, and proliferation [35,45,46,47,48,49]. NHEs mediate the signaling of growth factors and proton sensing [50,51,52] (Box 2).

Figure 4 Membrane carbonic anhydrase IX generates carbonic acid through hydration of CO2. Carbon dioxide diffuses from inside the cell and is a product of cellular metabolism. Carbonic acid is immediately ionized to bicarbonate and a proton. While the proton remains in the extracellular space contributing to its acidity, the bicarbonate ion is imported into the cell by NBC1 contributing to increasing pHi. CAIX (carbonic anhydrase 9) and CAXII (carbonic anhydrase 12) have been found to be potent drivers of cancer growth by alkalinizing the intracellular milieu [70].

Figure 5 V-ATPase proton pump mechanism of action.

Figure 6 Lactate extruder function of MCT4. Lactate originates from the enzymatic glycolysis of glucose introduced from the extracellular space with the mediation of glucose transporters (GLUTs). MCT4 is the main lactate exporter, while MCT1 imports lactate into the oxidative cells participating in the lactate shuttle.

Figure 7 The tandem work of NKCC1 and the Cl/CO3H exchanger alkalinize the intracellular milieu. Loop diuretics in general have the ability to inhibit NKCC1. The energy required for NKCC1 is provided by the electrochemical gradient of sodium [113,114,115,116,117]. The pHi stabilizing properties of the chloride/bicarbonate exchanger have been clearly demonstrated in osteoclasts [118] and kidneys. In cancer, it works in close association with cytoplasmic carbonic anhydrase II [119], with a final result of proton extrusion [120]. While NKCC1 increases intracellular Cl−, this molecule is re-exported by the exchanger, allowing the import of bicarbonate. Bicarbonate transport in cancer is a pivotal issue in the pH paradigm [121]. Disulfiram, a drug used to treat alcoholism, has been shown to decrease the activity of the chloride/bicarbonate exchanger [122].

Figure 8 Year 2017: Front view: rib metastasis, iliac bone metastasis, increased radionuclide caption at maxillary alveolar level. Dorsal view: 4–5 dorsal vertebra metastasis. These images were similar to those of 2014. Absence of right kidney due to radical nephrectomy in 2003. Left panel anterior view. Second panel posterior view. Four right panels: upper left: posterior view, upper right: anterior view, lower left: right ribs, lower right: left ribs.

Figure 9 Year 2018: Front view: rib metastasis, iliac bone metastasis, increased radionuclide caption at maxillary alveolar level. Stable disease.

ijms-21-09221-t001_Table 1Table 1 Drug scheme used in case 1.

DRUG	DOSE	NOTE	
Amiloride + Furosemide	5 mg + 40 mg three times a day.	This product is available on the market. The combination of Amiloride + Dihydrochlorotiazide can also be used. Potassium level control is required.	
Lansoprazole 	60 mg three times a day.	Other omeprazole derivatives can be used, namely esomeprazole, pantoprazole, etc. Our preference has been lansoprazole for the reasons explained above.	
Topiramate	200 mg daily. 	Starting dose 50 mg with weekly increase of 50 mg until reaching 200 mg	
Atorvastatin	15 mg twice a day.	
	
Quercetin	100 mg three times a day.	Over the counter product. Higher doses can be used without evidence of toxicity.	
Metformin	2 g a day	Tolerance was low and it was finally reduced to 500 mg a day.	
Acetazolamide	250 mg twice a day.	It was discontinued due to poor tolerance.	
Silymarin * (milk thistle) and silibinin	Normalized extract 200 mg twice a day	Silymarin extracts are MCT inhibitors [314] and have shown anti-tumor activity in renal cell carcinoma [315,316,317,318,319,320,321,322,323,324,325,326,327,328] and in other tumors as well [329,330,331,332].	
Celecoxib + aspirin **	200 mg a day + 300 mg	Aspirin was added to decrease cardiovascular risks of celecoxib.	
* Most of the anti-tumoral actions attributed to silymarin ingredients, like silibinin, are probably cytoplasm-acidification-independent. For a review on silibinin anti-tumoral effects, read Boojar et al. [333]. ** Aspirin is used as a preventive for celecoxib adverse events.
==== Refs
References
1. Mukherjee S.   The Emperor of All Maladies: A Biography of Cancer Simon and Schuster New York, NY, USA 2010 384 392 
2. Kinzler K.W.  Vogelstein B.   Lessons from hereditary colorectal cancer Cell 1996 87 159 170 10.1016/S0092-8674(00)81333-1 8861899 
3. Hanahan D.  Weinberg R.A.   The hallmarks of cancer Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931 
4. Hanahan D.  Weinberg R.A.   Hallmarks of cancer: The next generation Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230 
5. Reshkin S.J.  Bellizzi A.  Caldeira S.  Albarani V.  Malanchi I.  Poignee M.  Alunni-Fabbroni M.  Casavola V.  Tommasino M.   Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes FASEB J. 2000 14 2185 2197 10.1096/fj.00-0029com 11053239 
6. Warburg O.  Posener K.  Negelein E.   Uber den Stoffwechsel der Carcinomzelle Biochem. Z. 1924 152 309 344 10.1007/BF01726151 
7. Anghileri L.J.   Tumor growth inhibition by ammonium chloride-induced acidosis Int. J. Clin. Pharmacol. Biopharmacy 1975 12 320 326 
8. Harguindey S.  Gillis M.   Evolution and cancer: Possible relationships to changes in environmental hydrogen ion concentration J. Theor. Biol. 1980 86 487 492 10.1016/0022-5193(80)90347-1 7218821 
9. Albers C.  Van Den Kerckhoff W.  Vaupel P.  Müller-Klieser W.   Effect of CO2  and lactic acid on intracellular pH of ascites tumor cells Respir. Physiol. 1981 45 273 285 10.1016/0034-5687(81)90011-6 6800006 
10. Warburg O.   On the origin of cancer cells Science 1956 123 309 314 10.1126/science.123.3191.309 13298683 
11. Yamagata M.  Hasuda K.  Stamato T.  Tannock I.F.   The contribution of lactic acid to acidification of tumours: Studies of variant cells lacking lactate dehydrogenase Br. J. Cancer 1998 77 1726 1731 10.1038/bjc.1998.289 9667639 
12. Parks S.K.  Mueller-Klieser W.  Pouysségur J.   Lactate and acidity in the cancer microenvironment Annu. Rev. Cancer Biol. 2020 4 141 158 10.1146/annurev-cancerbio-030419-033556 
13. Mazzio E.  Badisa R.  Mack N.  Cassim S.  Zdralevic M.  Pouyssegur J.  Soliman K.F.   Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase Cancer Genom. Proteom. 2020 17 469 497 10.21873/cgp.20205 
14. Counillon L.  Pouysségur J.   The expanding family of eucaryotic Na+/H+ exchangers J. Biol. Chem. 2000 275 1 4 10.1074/jbc.275.1.1 10617577 
15. L’allemain G.  Paris S.  Pouysségur J.   Growth factor action and intracellular pH regulation in fibroblasts. Evidence for a major role of the Na+/H+ antiport J. Biol. Chem. 1984 259 5809 5815 6325450 
16. Busco G.  Cardone R.A.  Greco M.R.  Bellizzi A.  Colella M.  Antelmi E.  Mancini M.T.  Dell’Aquila M.E.  Casavola V.  Paradiso A.    NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space FASEB J. 2010 24 3903 3915 10.1096/fj.09-149518 20547664 
17. Reshkin S.J.  Bellizzi A.  Albarani V.  Guerra L.  Tommasino M.  Paradiso A.  Casavola V.   Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na+/H+ exchange, motility, and invasion induced by serum deprivation J. Biol. Chem. 2000 275 5361 5369 10.1074/jbc.275.8.5361 10681510 
18. Alfarouk K.O.  Verduzco D.  Rauch C.  Muddathir A.K.  Adil H.B.  Elhassan G.O.  Ibrahim M.E.  Orozco J.D.P.  Cardone R.A.  Reshkin S.J.    Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question Oncoscience 2014 1 777 10.18632/oncoscience.109 25621294 
19. Huber V.  De Milito A.  Harguindey S.  Reshkin S.J.  Wahl M.L.  Rauch C.  Chiesi A.  Pouysségur J.  Gatenby R.A.  Rivoltini L.    Proton dynamics in cancer J. Transl. Med. 2010 8 1 4 10.1186/1479-5876-8-57 20064266 
20. Harguindey S.  Arranz J.L.  Wahl M.L.  Orive G.  Reshkin S.J.   Proton transport inhibitors as potentially selective anticancer drugs Anticancer Res. 2009 29 2127 2136 19528473 
21. Paradiso A.  Cardone R.A.  Bellizzi A.  Bagorda A.  Guerra L.  Tommasino M.  Casavola V.  Reshkin S.J.   The Na+–H+ exchanger-1 induces cytoskeletal changes involving reciprocal RhoA and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells Breast Cancer Res. 2004 6 1 13 10.1186/bcr922 14680479 
22. Harguindey S.  Alfarouk K.  Orozco J.P.  Hardonniere K.  Stanciu D.  Fais S.  Devesa J.   A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics Int. J. Mol. Sci. 2020 21 1110 10.3390/ijms21031110 
23. Brahimi-Horn M.C.  Chiche J.  Pouysségur J.   Hypoxia and cancer J. Mol. Med. 2007 85 1301 1307 10.1007/s00109-007-0281-3 18026916 
24. Oginuma M.  Harima Y.  Tarazona O.A.  Diaz-Cuadros M.  Michaut A.  Ishitani T.  Xiong F.  Pourquié O.   Intracellular pH controls WNT downstream of glycolysis in amniote embryos Nature 2020 584 98 101 10.1038/s41586-020-2428-0 32581357 
25. Zheng T.  Jäättelä M.  Liu B.   pH gradient reversal fuels cancer progression Int. J. Biochem. Cell Biol. 2020 125 105796 10.1016/j.biocel.2020.105796 32593663 
26. Spugnini E.P.  Sonveaux P.  Stock C.  Perez-Sayans M.  De Milito A.  Avnet S.  Garcìa Garcìa A.  Harguindey A.  Fais S.   Proton channels and exchangers in cancer Biochim. Biophys. Acta (BBA)-Biomembr. 2015 1848 2715 2726 10.1016/j.bbamem.2014.10.015 
27. Gerson D.F.   Intracellular pH and the mitotic cycle in Physarum and mammalian cells Cell Cycle Regul. 1978 105 131 
28. Shen S.S.  Steinhardt R.A.   Intracellular pH controls the development of new potassium conductance after fertilization of the sea urchin egg Exp. Cell Res. 1980 125 55 61 10.1016/0014-4827(80)90188-3 7188689 
29. Inoue H.  Yoshioka T.   Measurement of intracellular pH in sea urchin eggs by 31P NMR J. Cell. Physiol. 1980 105 461 468 10.1002/jcp.1041050310 6780576 
30. Epel D.   Mechanisms of activation of sperm and egg during fertilization of sea urchin gametes Current Topics in Developmental Biology Academic Press New York, NY, USA 1978 Volume 12 185 246 
31. Moolenaar W.H.   Effects of growth factors on intracellular pH regulation Annu. Rev. Physiol. 1986 48 363 376 10.1146/annurev.ph.48.030186.002051 3010817 
32. Pouysségur J.  Sardet C.  Franchi A.  L’Allemain G.I.L.L.E.S.  Paris S.   A specific mutation abolishing Na+/H+ antiport activity in hamster fibroblasts precludes growth at neutral and acidic pH Proc. Natl. Acad. Sci. USA 1984 81 4833 4837 10.1073/pnas.81.15.4833 6087349 
33. Pedersen S.F.   The Na+/H+ exchanger NHE1 in stress-induced signal transduction: Implications for cell proliferation and cell death Pflügers Arch. 2006 452 249 10.1007/s00424-006-0044-y 16586098 
34. Wang H.  Singh D.  Fliegel L.   The Na+/H+ antiporter potentiates growth and retinoic acid-induced differentiation of P19 embryonal carcinoma cells J. Biol. Chem. 1997 272 26545 26549 10.1074/jbc.272.42.26545 9334233 
35. Besson P.  Fernandez-Rachubinski F.  Yang W.  Fliegel L.   Regulation of Na+/H+ exchanger gene expression: Mitogenic stimulation increases NHE1 promoter activity Am. J. Physiol. Cell Physiol. 1998 274 C831 C839 10.1152/ajpcell.1998.274.3.C831 
36. Flinck M.  Kramer S.H.  Schnipper J.  Andersen A.P.  Pedersen S.F.   The acid-base transport proteins NHE1 and NBCn1 regulate cell cycle progression in human breast cancer cells Cell Cycle 2018 17 1056 1067 10.1080/15384101.2018.1464850 29895196 
37. Cardone R.A.  Greco M.R.  Zeeberg K.  Zaccagnino A.  Saccomano M.  Bellizzi A.  Bruns P.  Menga M.  Pilarsky C.  Schwab A.    A novel NHE1-centered signaling cassette drives epidermal growth factor receptor–dependent pancreatic tumor metastasis and is a target for combination therapy Neoplasia 2015 17 155 166 10.1016/j.neo.2014.12.003 25748234 
38. Jensen H.H.  Pedersen G.A.  Morgen J.J.  Parsons M.  Pedersen S.F.  Nejsum L.N.   The Na+/H+ exchanger NHE1 localizes as clusters to cryptic lamellipodia and accelerates collective epithelial cell migration J. Physiol. 2019 597 849 867 10.1113/JP277383 30471113 
39. Stock C.  Pedersen S.F.   Roles of pH and the Na+/H+ exchanger NHE1 in cancer: From cell biology and animal models to an emerging translational perspective? Seminars in Cancer Biology Academic Press New York, NY, USA 2017 Volume 43 5 16 
40. Amith S.R.  Fliegel L.   Regulation of the Na+/H+ exchanger (NHE1) in breast cancer metastasis Cancer Res. 2013 73 1259 1264 10.1158/0008-5472.CAN-12-4031 23393197 
41. Lauritzen G.  Stock C.M.  Lemaire J.  Lund S.F.  Jensen M.F.  Damsgaard B.  Petersen K.S.  Wiwel M.  Rønnov-Jessen L.  Schwab A.    The Na+/H+ exchanger NHE1, but not the Na+, HCO3 -cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2 Cancer Lett. 2012 317 172 183 10.1016/j.canlet.2011.11.023 22120673 
42. Cong D.  Zhu W.  Shi Y.  Pointer K.B.  Clark P.A.  Shen H.  Kuo J.S.  Hu S.  Sun D.   Upregulation of NHE1 protein expression enables glioblastoma cells to escape TMZ-mediated toxicity via increased H+ extrusion, cell migration and survival Carcinogenesis 2014 35 2014 2024 10.1093/carcin/bgu089 24717311 
43. Bianchini L.  L’Allemain G.  Pouysségur J.   The p42/p44 mitogen-activated protein kinase cascade is determinant in mediating activation of the Na+/H+ exchanger (NHE1 isoform) in response to growth factors J. Biol. Chem. 1997 272 271 279 10.1074/jbc.272.1.271 8995258 
44. Xia J.  Huang N.  Huang H.  Sun L.  Dong S.  Su J.  Zhang J.  Wang L.  Lin L.  Shi M.    Voltage-gated sodium channel Nav1. 7 promotes gastric cancer progression through MACC1-mediated upregulation of NHE1 Int. J. Cancer 2016 139 2553 2569 10.1002/ijc.30381 27529686 
45. Putney L.K.  Barber D.L.   Expression profile of genes regulated by activity of the Na-H exchanger NHE1 BMC Genom. 2004 5 46 10.1186/1471-2164-5-46 
46. Zhu W.  Carney K.E.  Pigott V.M.  Falgoust L.M.  Clark P.A.  Kuo J.S.  Sun D.   Glioma-mediated microglial activation promotes glioma proliferation and migration: Roles of Na+/H+ exchanger isoform 1 Carcinogenesis 2016 37 839 851 10.1093/carcin/bgw068 27287871 
47. Malo M.E.  Fliegel L.   Physiological role and regulation of the Na+/H+ exchanger Can. J. Physiol. Pharmacol. 2006 84 1081 1095 10.1139/y06-065 17218973 
48. Moor A.N.  Fliegel L.   Protein kinase-mediated regulation of the Na+/H+ exchanger in the rat myocardium by mitogen-activated protein kinase-dependent pathways J. Biol. Chem. 1999 274 22985 22992 10.1074/jbc.274.33.22985 10438464 
49. Flinck M.  Kramer S.H.  Pedersen S.F.   Roles of pH in control of cell proliferation Acta Physiol. 2018 223 e13068 10.1111/apha.13068 
50. Wakabayashi S.  Fafournoux P.  Sardet C.  Pouyssegur J.   The Na+/H+ antiporter cytoplasmic domain mediates growth factor signals and controls “H (+)-sensing” Proc. Natl. Acad. Sci. USA 1992 89 2424 2428 10.1073/pnas.89.6.2424 1372444 
51. Wakabayashi S.  Bertrand B.  Shigekawa M.  Fafournoux P.  Pouysségur J.   Growth factor activation and “H (+)-sensing” of the Na+/H+ exchanger isoform 1 (NHE1). Evidence for an additional mechanism not requiring direct phosphorylation J. Biol. Chem. 1994 269 5583 5588 8119893 
52. Pouysségur J.   The growth factor-activatable Na+/H+ exchange system: A genetic approach Trends Biochem. Sci. 1985 10 453 455 10.1016/0968-0004(85)90030-1 
53. Strapcova S.  Takacova M.  Csaderova L.  Martinelli P.  Lukacikova L.  Gal V.  Kopacek J.  Svastova E.   Clinical and pre-clinical evidence of carbonic anhydrase ix in pancreatic cancer and its high expression in pre-cancerous lesions Cancers 2020 12 2005 10.3390/cancers12082005 
54. Kajanova I.  Zatovicova M.  Jelenska L.  Sedlakova O.  Barathova M.  Csaderova L.  Debreova M.  Lukacikova L.  Grossmannova K.  Labudova M.    Impairment of carbonic anhydrase IX ectodomain cleavage reinforces tumorigenic and metastatic phenotype of cancer cells Br. J. Cancer 2020 122 1590 1603 10.1038/s41416-020-0804-z 32210366 
55. Koruza K.  Murray A.B.  Mahon B.P.  Hopkins J.B.  Knecht W.  McKenna R.  Fisher S.Z.   Biophysical Characterization of Cancer-Related Carbonic Anhydrase IX Int. J. Mol. Sci. 2020 21 5277 10.3390/ijms21155277 
56. Lee S.H.  Griffiths J.R.   How and Why Are Cancers Acidic? Carbonic Anhydrase IX and the Homeostatic Control of Tumour Extracellular pH Cancers 2020 12 1616 10.3390/cancers12061616 
57. Logozzi M.  Mizzoni D.  Capasso C.  Del Prete S.  Di Raimo R.  Falchi M.  Angelini D.F.  Sciarra A.  Maggi M.  Supuran C.T.    Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH J. Enzym. Inhib. Med. Chem. 2020 35 280 288 10.1080/14756366.2019.1697249 
58. Vergara D.  Ravaioli S.  Fonzi E.  Adamo L.  Damato M.  Bravaccini S.  Pirini F.  Gaballo A.  Barbano R.  Pasculli B.    Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling Int. J. Mol. Sci. 2020 21 715 10.3390/ijms21030715 
59. Supuran C.T.   Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors Expert Opin. Investig. Drugs 2018 27 963 970 10.1080/13543784.2018.1548608 
60. Wang B.  Jiang H.  Wan X.  Wang Y.  Zheng X.  Li P.  Guo J.  Ding X.  Song H.   Carbonic anhydrase IV inhibits cell proliferation in gastric cancer by regulating the cell cycle Oncol. Lett. 2020 20 1 10.3892/ol.2020.11865 32774475 
61. Chu Y.H.  Su C.W.  Hsieh Y.S.  Chen P.N.  Lin C.W.  Yang S.F.   Carbonic Anhydrase III Promotes Cell Migration and Epithelial–Mesenchymal Transition in Oral Squamous Cell Carcinoma Cells 2020 9 704 10.3390/cells9030704 
62. Pastorekova S.  Gillies R.J.   The role of carbonic anhydrase IX in cancer development: Links to hypoxia, acidosis, and beyond Cancer Metastasis Rev. 2019 38 65 77 10.1007/s10555-019-09799-0 31076951 
63. Vitoratou D.I.  Tolia M.  Liakos P.  Tsoukalas N.  Giaginis C.  Nikolaou M.  Nikolaou G.  Rigas G.  Psarianos K.  Lioupis A.    Clinical value of significance of Hypoxia Inducible Factor-1α, Glucose Transporter-1 and Carbonic Anhydrase IX in rectal cancer after preoperative chemoradiotherapy J. Buon 2019 24 456 463 31127991 
64. Smyth L.G.  O’hurley G.  O’grady A.  Fitzpatrick J.M.  Kay E.  Watson R.W.G.   Carbonic anhydrase IX expression in prostate cancer Prostate Cancer Prostatic Dis. 2010 13 178 181 10.1038/pcan.2009.58 20038959 
65. Lee D.  Hong J.H.   The fundamental role of bicarbonate transporters and associated carbonic anhydrase enzymes in maintaining ion and pH homeostasis in non-secretory organs Int. J. Mol. Sci. 2020 21 339 10.3390/ijms21010339 
66. Hong J.H.  Muhammad E.  Zheng C.  Hershkovitz E.  Alkrinawi S.  Loewenthal N.  Parvari R.  Muallem S.   Essential role of carbonic anhydrase XII in secretory gland fluid and HCO3− secretion revealed by disease causing human mutation J. Physiol. 2015 593 5299 5312 10.1113/JP271378 26486891 
67. Svastova E.  Witarski W.  Csaderova L.  Kosik I.  Skvarkova L.  Hulikova A.  Zatovicova M.  Barathova M.  Kopacek J.  Pastorek J.    Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain J. Biol. Chem. 2012 287 3392 3402 10.1074/jbc.M111.286062 22170054 
68. Parks S.K.  Pouyssegur J.   The Na+/HCO3− Co-Transporter SLC4APlays a Role in Growth and Migration of Colon and Breast Cancer Cells J. Cell. Physiol. 2015 230 1954 1963 10.1002/jcp.24930 25612232 
69. Villafuerte F.C.  Swietach P.  Youm J.B.  Ford K.  Cardenas R.  Supuran C.T.  Cobden P.M.  Rohling M.  Vaughan-Jones R.D.   Facilitation by intracellular carbonic anhydrase of Na+–HCO3− co-transport but not Na+/H+ exchange activity in the mammalian ventricular myocyte J. Physiol. 2014 592 991 1007 10.1113/jphysiol.2013.265439 24297849 
70. Chiche J.  Ilc K.  Laferriere J.  Trottier E.  Dayan F.  Mazure N.M.  Brahimi-Horn M.C.  Pouysségur J.   Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH Cancer Res. 2009 69 358 368 10.1158/0008-5472.CAN-08-2470 19118021 
71. You H.  Jin J.  Shu H.  Yu B.  De Milito A.  Lozupone F.  Deng Y.  Tang N.  Yao G.  Gu J.    Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells Cancer Lett. 2009 280 110 119 10.1016/j.canlet.2009.02.023 19299075 
72. Lu Z.N.  Tian B.  Guo X.L.   Repositioning of proton pump inhibitors in cancer therapy Cancer Chemother. Pharmacol. 2017 80 925 937 10.1007/s00280-017-3426-2 28861639 
73. Ikemura K.  Hiramatsu S.  Okuda M.   Drug repositioning of proton pump inhibitors for enhanced efficacy and safety of cancer chemotherapy Front. Pharmacol. 2017 8 911 10.3389/fphar.2017.00911 29311921 
74. Zhang B.  Yang Y.  Shi X.  Liao W.  Chen M.  Cheng A.S.L.  Yan H.  Fang C.  Zhang S.  Xu G.    Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial–mesenchymal transition Cancer Lett. 2015 356 704 712 10.1016/j.canlet.2014.10.016 25449432 
75. Spugnini E.  Fais S.   Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering? Seminars in Cancer Academic Press New York, NY, USA 2017 Volume 43 111 118 
76. Lindner K.  Borchardt C.  Schöpp M.  Bürgers A.  Stock C.  Hussey D.J.  Haier J.  Hummel R.   Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer J. Exp. Clin. Cancer Res. 2014 33 73 10.1186/s13046-014-0073-x 25175076 
77. Cheung K.S.  Chan E.W.  Wong A.Y.  Chen L.  Wong I.C.  Leung W.K.   Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: A population-based study Gut 2018 67 28 35 10.1136/gutjnl-2017-314605 29089382 
78. Brusselaers N.  Wahlin K.  Engstrand L.  Lagergren J.   Maintenance therapy with proton pump inhibitors and risk of gastric cancer: A nationwide population-based cohort study in Sweden BMJ Open 2017 7 10.1136/bmjopen-2017-017739 
79. Cheung K.S.  Leung W.K.   Long-term use of proton-pump inhibitors and risk of gastric cancer: A review of the current evidence Ther. Adv. Gastroenterol. 2019 12 1756284819834511 10.1177/1756284819834511 
80. Brusselaers N.  Lagergren J.  Engstrand L.   Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer Cancer Epidemiol. 2019 62 101585 10.1016/j.canep.2019.101585 31445426 
81. Payen V.L.  Mina E.  Van Hée V.F.  Porporato P.E.  Sonveaux P.   Monocarboxylate transporters in cancer Mol. Metab. 2020 33 48 66 10.1016/j.molmet.2019.07.006 31395464 
82. Panisova E.  Kery M.  Sedlakova O.  Brisson L.  Debreova M.  Sboarina M.  Sonveaux P.  Pastorekova S.  Svastova E.   Lactate stimulates CA IX expression in normoxic cancer cells Oncotarget 2017 8 77819 10.18632/oncotarget.20836 29100428 
83. Izumi H.  Takahashi M.  Uramoto H.  Nakayama Y.  Oyama T.  Wang K.Y.  Sasaguri Y.  Nishizawa S.  Kohno K.   Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells Cancer Sci. 2011 102 1007 1013 10.1111/j.1349-7006.2011.01908.x 21306479 
84. Pinheiro C.  Reis R.M.  Ricardo S.  Longatto-Filho A.  Schmitt F.  Baltazar F.   Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44 BioMed Res. Int. 2010 2010 10.1155/2010/427694 
85. Johnson J.M.  Cotzia P.  Fratamico R.  Mikkilineni L.  Chen J.  Colombo D.  Mollaee M.  Whitaker-Menezes D.  Domingo-Vidal M.  Lin Z.    MCT1 in invasive ductal carcinoma: Monocarboxylate metabolism and aggressive breast cancer Front. Cell Dev. Biol. 2017 5 27 10.3389/fcell.2017.00027 28421181 
86. Kim H.K.  Lee I.  Bang H.  Kim H.C.  Lee W.Y.  Yun S.H.  Lee J.  Lee S.J.  Park Y.S.  Kim K.M.    MCT4 expression is a potential therapeutic target in colorectal cancer with peritoneal carcinomatosis Mol. Cancer Ther. 2018 17 838 848 10.1158/1535-7163.MCT-17-0535 29483215 
87. Lee J.Y.  Lee I.  Chang W.J.  Ahn S.M.  Lim S.H.  Kim H.S.  Yoo K.H.  Jung K.S.  Song H.N.  Cho J.H.    MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis Oncotarget 2016 7 43492 10.18632/oncotarget.9523 27224918 
88. Kim Y.  Choi J.W.  Lee J.H.  Kim Y.S.   Expression of lactate/H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: Immunohistochemical and The Cancer Genome Atlas data analyses Hum. Pathol. 2015 46 104 112 10.1016/j.humpath.2014.09.013 25456395 
89. Pértega-Gomes N.  Vizcaíno J.R.  Miranda-Gonçalves V.  Pinheiro C.  Silva J.  Pereira H.  Monteiro P.  Henrique R.M.  Reis R.M.  Lopes C.    Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer BMC Cancer 2011 11 1 9 10.1186/1471-2407-11-312 21194487 
90. Dhup S.  Kumar Dadhich R.  Ettore Porporato P.  Sonveaux P.   Multiple biological activities of lactic acid in cancer: Influences on tumor growth, angiogenesis and metastasis Curr. Pharm. Des. 2012 18 1319 1330 10.2174/138161212799504902 22360558 
91. Choi SY C.  Collins C.C.  Gout P.W.  Wang Y.   Cancer-generated lactic acid: A regulatory, immunosuppressive metabolite? J. Pathol. 2013 230 350 355 10.1002/path.4218 23729358 
92. Le A.  Cooper C.R.  Gouw A.M.  Dinavahi R.  Maitra A.  Deck L.M.  Royer R.E.  Vander Jagt D.L.  Semenza G.L.  Dang C.V.   Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression Proc. Natl. Acad. Sci. USA 2010 107 2037 2042 10.1073/pnas.0914433107 20133848 
93. Fiume L.  Manerba M.  Vettraino M.  Di Stefano G.   Inhibition of lactate dehydrogenase activity as an approach to cancer therapy Future Med. Chem. 2014 6 429 445 10.4155/fmc.13.206 24635523 
94. Koltai T.   Cancer: Fundamentals behind pH targeting and the double-edged approach Oncotargets Ther. 2016 9 6343 10.2147/OTT.S115438 
95. Benjamin D.  Robay D.  Hindupur S.K.  Pohlmann J.  Colombi M.  El-Shemerly M.Y.  Maira S.M.  Moroni C.  Lane H.A.  Hall M.N.   Dual inhibition of the lactate transporters MCT1 and MCT4 is synthetic lethal with metformin due to NAD+ depletion in cancer cells Cell Rep. 2018 25 3047 3058 10.1016/j.celrep.2018.11.043 30540938 
96. Benjamin D.  Colombi M.  Hindupur S.K.  Betz C.  Lane H.A.  El-Shemerly M.Y.  Lu M.  Quagliata L.  Terracciano L.  Moes S.    Syrosingopine sensitizes cancer cells to killing by metformin Sci. Adv. 2016 2 e1601756 10.1126/sciadv.1601756 28028542 
97. Lee Z.W.  Teo X.Y.  Song Z.J.  Nin D.S.  Novera W.  Choo B.A.  Dymock B.W.  Moore P.K.  Huang R.Y.J.  Deng L.W.   Intracellular hyper-acidification potentiated by hydrogen sulfide mediates invasive and therapy resistant cancer cell death Front. Pharmacol. 2017 8 763 10.3389/fphar.2017.00763 29163155 
98. Plummer A.J.  Barrett W.E.  Maxwell R.A.  Finocchio D.  Lucas R.A.  Earl A.E.   Hypotensive properties of syrosingopine SU-3118, an ester of methyl reserpate Arch. Int. Pharmacodyn. Ther. 1959 119 245 257 13628284 
99. Sosa G.  Morita Y.  Mader I.J.   A Double Blind Evaluation of the Antihypertensive Effect of Reserpine, Phenobarbital, Hydralazine, Syrosingopine, and Placebo in Ambulatory Subjects Angiology 1960 11 381 386 10.1177/000331976001100503 
100. Shelburne P.F.  Orgain E.S.   Comparison of syrosingopine and reserpine in the treatment of ambulatory hypertensive patients Am. J. Med. Sci. 1963 245 304 10.1097/00000441-196303000-00013 13977067 
101. Lisan P.  Balaban S.A.   Hydrochlorothiazide and syrosingopine in the control of hypertension J. Am. Geriatr. Soc. 1960 8 803 805 10.1111/j.1532-5415.1960.tb00096.x 13762632 
102. Benjamin D.  Colombi M.  Hall M.  Moroni C.   Washington, DC: U.S. Patent and Trademark Office U.S. Patent US8993587B2 31 3 2015 Available online: https://patents.google.com/patent/US8993587B2/en  (accessed on 1 December 2020) 
103. Gardner H.L.  Fenger J.M.  London C.A.   Abstract B081: Regulation and function of monocarboxylate transporters in osteosarcoma Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Boston, MA, USA 26–30 October 2019 10.1158/1535-7163.TARG-19-B081 
104. Zhang Z.  Ji J.  Liu H.   Drug Repurposing in Oncology: Current Evidence and Future Direction Curr. Med. Chem. 2020 10.2174/0929867327999200820124111 33109032 
105. Shiozaki A.  Nako Y.  Ichikawa D.  Konishi H.  Komatsu S.  Kubota T.  Fujiwara H.  Okamoto K.  Kishimoto M.  Marunaka Y.    Role of the Na+/K+/2Cl-cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell carcinoma World J. Gastroenterol. WJG 2014 20 6844 10.3748/wjg.v20.i22.6844 24944475 
106. Ma H.  Li T.  Tao Z.  Hai L.  Tong L.  Yi L.  Abeysekera I.R.  Liu P.  Xie Y.  Li J.    NKCC1 promotes EMT-like process in GBM via RhoA and Rac1 signaling pathways J. Cell. Physiol. 2019 234 1630 1642 10.1002/jcp.27033 30159893 
107. Schiapparelli P.  Guerrero-Cazares H.  Magaña-Maldonado R.  Hamilla S.M.  Ganaha S.  Fernandes E.G.L.  Huang C.H.  Aranda-Espinoza H.  Devreotes P.  Quinones-Hinojosa A.   NKCC1 regulates migration ability of glioblastoma cells by modulation of actin dynamics and interacting with cofilin EBioMedicine 2017 21 94 103 10.1016/j.ebiom.2017.06.020 28679472 
108. Sun P.L.  Jin Y.  Park S.Y.  Kim H.  Park E.  Jheon S.  Kim K.  Lee C.T.  Chung J.H.   Expression of Na+–K+-2Cl− cotransporter isoform 1 (NKCC1) predicts poor prognosis in lung adenocarcinoma and EGFR-mutated adenocarcinoma patients QJM Int. J. Med. 2016 109 237 244 10.1093/qjmed/hcv207 
109. Pedersen S.F.  O’Donnell M.E.  Anderson S.E.  Cala P.M.   Physiology and pathophysiology of Na+/H+ exchange and Na+-K+-2Cl− cotransport in the heart, brain, and blood Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006 291 R1 R25 10.1152/ajpregu.00782.2005 16484438 
110. Parkes J.L.  Coleman P.S.   Enhancement of carbonic anhydrase activity by erythrocyte membranes Arch. Biochem. Biophys. 1989 275 459 468 10.1016/0003-9861(89)90392-5 2512855 
111. Vince J.W.  Reithmeier R.A.   Identification of the carbonic anhydrase II binding site in the Cl-/HCO3-anion exchanger AE1 Biochemistry 2000 39 5527 5533 10.1021/bi992564p 10820026 
112. Sterling D.  Reithmeier R.A.  Casey J.R.   A transport metabolon Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers J. Biol. Chem. 2001 276 47886 47894 10.1074/jbc.M105959200 11606574 
113. Haas M.   The Na-K-Cl cotransporters Am. J. Physiol. Cell Physiol. 1994 267 C869 C885 10.1152/ajpcell.1994.267.4.C869 
114. Haas M.  Forbush B.   The Na-K-Cl cotransporters J. Bioenergy Biomembr. 1998 30 161 172 10.1023/A:1020521308985 
115. Garneau A.P.  Isenring P.   The structure of Na+-K+-Cl− cotransporter 1 Nat. Rev. Nephrol. 2019 15 732 734 10.1038/s41581-019-0204-x 31506608 
116. Sinning A.  Radionov N.  Trepiccione F.  López-Cayuqueo K.I.  Jayat M.  Baron S.  Cornière N.  Alexander R.T.  Hadchouel J.  Eladari D.    Double knockout of the Na+-driven Cl−/HCO3− exchanger and Na+/Cl− cotransporter induces hypokalemia and volume depletion J. Am. Soc. Nephrol. 2017 28 130 139 10.1681/ASN.2015070734 27151921 
117. Chew T.A.  Orlando B.J.  Zhang J.  Latorraca N.R.  Wang A.  Hollingsworth S.A.  Chen D.H.  Dror R.O.  Liao M.  Feng L.   Structure and mechanism of the cation–chloride cotransporter NKCC1 Nature 2019 572 488 492 10.1038/s41586-019-1438-2 31367042 
118. Teti A.  Blair H.C.  Teitelbaum S.L.  Kahn A.J.  Koziol C.  Konsek J.  Zambonin-Zallone A.  Schlesinger P.H.   Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts J. Clin. Investig. 1989 83 227 233 10.1172/JCI113863 2910910 
119. Sterling D.  Brown N.J.  Supuran C.T.  Casey J.R.   The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II Am. J. Physiol. Cell Physiol. 2002 283 C1522 C1529 10.1152/ajpcell.00115.2002 12372813 
120. Potter C.P.S.  Harris A.L.   Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer Br. J. Cancer 2003 89 2 7 10.1038/sj.bjc.6600936 12838292 
121. Gorbatenko A.  Olesen C.W.  Boedtkjer E.  Pedersen S.F.   Regulation and roles of bicarbonate transport in cancer Front. Physiol. 2014 5 130 10.3389/fphys.2014.00130 24795638 
122. Hwang S.  Shin D.M.  Hong J.H.   Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger Modulation to Inhibit Cancer Cell Migration Molecules 2019 24 3409 10.3390/molecules24183409 
123. Brandt C.  Nozadze M.  Heuchert N.  Rattka M.  Löscher W.   Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy J. Neurosci. 2010 30 8602 8612 10.1523/JNEUROSCI.0633-10.2010 20573906 
124. Gharaylou Z.  Tafakhori A.  Agah E.  Aghamollaii V.  Kebriaeezadeh A.  Hadjighassem M.   A preliminary study evaluating the safety and efficacy of bumetanide, an NKCC1 inhibitor, in patients with drug-resistant epilepsy CNS Drugs 2019 33 283 291 10.1007/s40263-019-00607-5 30784026 
125. Tian Y.  Guo S.X.  Li J.R.  Du H.G.  Wang C.H.  Zhang J.M.  Wu Q.   Topiramate attenuates early brain injury following subarachnoid haemorrhage in rats via duplex protection against inflammation and neuronal cell death Brain Res. 2015 1622 174 185 10.1016/j.brainres.2015.06.007 26086367 
126. Grabmaier K.  de Weijert M.C.  Verhaegh G.W.  Schalken J.A.  Oosterwijk E.   Strict regulation of CAIX G250/MN by HIF-1 α in clear cell renal cell carcinoma Oncogene 2004 23 5624 5631 10.1038/sj.onc.1207764 15184875 
127. Kaluz S.  Kaluzová M.  Stanbridge E.J.   Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer Cancer Res. 2003 63 917 922 12615703 
128. Façanha A.O.  Dos Reis M.C.  Montero-Lomeli M.   Structural study of the porcine Na+/H+ exchanger NHE1 gene and its 5′-flanking region Mol. Cell. Biochem. 2000 210 91 99 10.1023/A:1007147426838 10976762 
129. Hua P.  Xu H.  Uno J.K.  Lipko M.A.  Dong J.  Kiela P.R.  Ghishan F.K.   Sp1 and Sp3 mediate NHE2 gene transcription in the intestinal epithelial cells Am. J. Physiol. Gastrointest. Liver Physiol. 2007 293 G146 G153 10.1152/ajpgi.00443.2006 17379926 
130. Amin M.R.  Dudeja P.K.  Ramaswamy K.  Malakooti J.   Involvement of Sp1 and Sp3 in differential regulation of human NHE3 promoter activity by sodium butyrate and IFN-γ/TNF-α Am. J. Physiol. Gastrointest. Liver Physiol. 2007 293 G374 G382 10.1152/ajpgi.00128.2007 17540780 
131. Song P.  Feng Z.  Riederer B.  Krabbenhöft A.  Rausch B.  Anstätt M.  Bantel J.  Lamlé J.  Vogel A.  Soleimani M.    Effect of Genetic Ablation of the Acid/Base Transporters PNBC1, NHE1, NHE2, and Slc26a7, On Gastric Epithelial Functions Gastroenterology 2009 136 A-125 10.1016/S0016-5085(09)60558-8 
132. Saha A.  Hammond C.E.  Gooz M.  Smolka A.J.   The role of Sp1 in IL-1β and H. pylori-mediated regulation of H, K-ATPase gene transcription Am. J. Physiol. Gastrointest. Liver Physiol. 2018 295 G977 G986 10.1152/ajpgi.90338.2008 
133. Torigoe T.  Izumi H.  Yoshida Y.  Ishiguchi H.  Okamoto T.  Itoh H.  Kohno K.   Low pH enhances SpDNA binding activity and interaction with TBP Nucleic Acids Res. 2003 31 4523 4530 10.1093/nar/gkg487 12888513 
134. Asanuma K.  Tsuji N.  Endoh T.  Yagihashi A.  Watanabe N.   Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells J. Immunol. 2004 172 3922 3929 10.4049/jimmunol.172.6.3922 15004200 
135. Bajpai R.  Nagaraju G.P.   Specificity protein 1: Its role in colorectal cancer progression and metastasis Crit. Rev. Oncol. Hematol. 2017 113 1 7 10.1016/j.critrevonc.2017.02.024 28427500 
136. Zhang Q.  Sun L.  Yin L.  Ming J.  Zhang S.  Luo W.  Qiu X.   CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer Tumor Biol. 2013 34 2703 2708 10.1007/s13277-013-0822-z 
137. Safe S.  Imanirad P.  Sreevalsan S.  Nair V.  Jutooru I.   Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target Expert Opin. Ther. Targets 2014 18 759 769 10.1517/14728222.2014.914173 24793594 
138. Abdelrahim M.  Baker C.H.  Abbruzzese J.L.  Safe S.   Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation J. Natl. Cancer Inst. 2006 98 855 868 10.1093/jnci/djj232 16788159 
139. Shelake S.  Sankpal U.T.  Bowman W.P.  Wise M.  Ray A.  Basha R.   Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth Investig. New Drugs 2017 35 158 165 10.1007/s10637-016-0417-9 28025760 
140. Jia Z.  Gao Y.  Wang L.  Li Q.  Zhang J.  Le X.  Wei D.  Yao J.C.  Chang D.Z.  Huang S.    Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity Cancer Res. 2010 70 1111 1119 10.1158/0008-5472.CAN-09-3282 20086170 
141. Sankpal U.T.  Goodison S.  Jones-Pauley M.  Hurtado M.  Zhang F.  Basha R.   Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells Oncotarget 2017 8 14593 10.18632/oncotarget.14651 28099934 
142. Ha T.  Lou Z.  Baek S.J.  Lee S.H.   Tolfenamic acid downregulates β-catenin in colon cancer Int. Immunopharmacol. 2016 35 287 293 10.1016/j.intimp.2016.04.008 27089389 
143. Sun J.  Tao R.  Mao T.  Feng Z.  Guo Q.  Zhang X.   The involvement of lipid raft pathway in suppression of TGFβ-mediated metastasis by tolfenamic acid in hepatocellular carcinoma cells Toxicol. Appl. Pharmacol. 2019 380 114696 10.1016/j.taap.2019.114696 31381904 
144. Ertekin R.  Ozkurt M.  Kus G.  Kabadere S.   Possible Antiproliferative Effect of Tolfenamic Acid on Human LNCaP Prostate Cancer Cell Lines Pak. J. Zool. 2019 51 1203 1598 10.17582/journal.pjz/2019.51.4.1413.1419 
145. Jittreetat T.  Shin Y.S.  Hwang H.S.  Lee B.S.  Kim Y.S.  Sannikorn P.  Kim C.H.   Tolfenamic acid inhibits the proliferation, migration, and invasion of nasopharyngeal carcinoma: Involvement of p38-mediated down-regulation of slug Yonsei Med. J. 2016 57 588 598 10.3349/ymj.2016.57.3.588 26996556 
146. Chang J.W.  Kang S.U.  Choi J.W.  Shin Y.S.  Baek S.J.  Lee S.H.  Kim C.H.   Tolfenamic Acid Induces Apoptosis and Growth Inhibition in Anaplastic Thyroid Cancer: Involvement of NAG-1 and Intracellular ROS Generation Free Radic. Biol. Med. 2014 67 115 130 10.1016/j.freeradbiomed.2013.10.818 24216474 
147. Hurtado M.  Sankpal U.T.  Kaba A.  Mahammad S.  Chhabra J.  Brown D.T.  Gurung R.K.  Holder A.A.  Vishwanatha J.K.  Basha R.   Novel survivin inhibitor for suppressing pancreatic cancer cells growth via downregulating Sp1 and Sp3 transcription factors Cell. Physiol. Biochem. 2018 51 1894 1907 10.1159/000495715 30504717 
148. Zhang Y.  Mantravadi P.K.  Jobbagy S.  Bao W.  Koh J.T.   Antagonizing the androgen receptor with a biomimetic acyltransferase ACS Chem. Biol. 2016 11 2797 2802 10.1021/acschembio.6b00659 27548116 
149. Kwon Y.J.  Cho N.H.  Ye D.J.  Baek H.S.  Ryu Y.S.  Chun Y.J.   Cytochrome P450 1B1 promotes cancer cell survival via specificity protein 1 (Sp1)-mediated suppression of death receptor 4 J. Toxicol. Environ. Health 2018 81 278 287 10.1080/15287394.2018.1440186 
150. Safe S.  Abbruzzese J.  Abdelrahim M.  Hedrick E.   Specificity protein transcription factors and cancer: Opportunities for drug development Cancer Prev. Res. 2018 11 371 382 10.1158/1940-6207.CAPR-17-0407 29545399 
151. Hedrick E.  Cheng Y.  Jin U.H.  Kim K.  Safe S.   Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells Oncotarget 2016 7 22245 10.18632/oncotarget.7925 26967243 
152. El-Kenawi A.  Dhillon J.  Ibrahim-Hashim A.  Abrahams D.  Pilon-Thomas S.  Ruffell B.  Gatenby R.  Gillies R.   Role of tumor generated acidity in immune stromal interactions during prostate carcinogenesis Cancer Res. 2017 10.1158/1538-7445 
153. Peppicelli S.  Andreucci E.  Ruzzolini J.  Margheri F.  Laurenzana A.  Bianchini F.  Calorini L.   Acidity of microenvironment as a further driver of tumor metabolic reprogramming J. Clin. Cell Immunol. 2017 8 2 10.4172/2155-9899.1000485 
154. Peppicelli S.  Bianchini F.  Calorini L.   Extracellular acidity, a “reappreciated” trait of tumor environment driving malignancy: Perspectives in diagnosis and therapy Cancer Metastasis Rev. 2014 33 823 832 10.1007/s10555-014-9506-4 24984804 
155. Estrella V.  Chen T.  Lloyd M.  Wojtkowiak J.  Cornnell H.H.  Ibrahim-Hashim A.  Bailey K.  Balagurunathan Y.  Rothberg J.M.  Sloane B.F.    Acidity generated by the tumor microenvironment drives local invasion Cancer Res. 2013 73 1524 1535 10.1158/0008-5472.CAN-12-2796 23288510 
156. Robey I.F.  Baggett B.K.  Kirkpatrick N.D.  Roe D.J.  Dosescu J.  Sloane B.F.  Hashim A.I.  Morse D.L.  Raghunand N.  Gatenby R.A.    Bicarbonate increases tumor pH and inhibits spontaneous metastases Cancer Res. 2009 69 2260 2268 10.1158/0008-5472.CAN-07-5575 19276390 
157. Peppicelli S.  Andreucci E.  Ruzzolini J.  Laurenzana A.  Margheri F.  Fibbi G.  Del Rosso M.  Bianchini F.  Calorini L.   The acidic microenvironment as a possible niche of dormant tumor cells Cell. Mol. Life Sci. 2017 74 2761 2771 10.1007/s00018-017-2496-y 28331999 
158. Pilon-Thomas S.  Kodumudi K.N.  El-Kenawi A.E.  Russell S.  Weber A.M.  Luddy K.  Damaghi M.  Wojtkowiak J.W.  Mulé J.J.  Ibrahim-Hashim A.    Neutralization of tumor acidity improves antitumor responses to immunotherapy Cancer Res. 2016 76 1381 1390 10.1158/0008-5472.CAN-15-1743 26719539 
159. Mahoney K.M.  Freeman G.J.   Acidity changes immunology: A new VISTA pathway Nat. Immunol. 2020 21 13 16 10.1038/s41590-019-0563-2 31822869 
160. Calcinotto A.  Filipazzi P.  Grioni M.  Iero M.  De Milito A.  Ricupito A.  Cova A.  Canese R.  Jachetti E.  Rossetti M.    Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes Cancer Res. 2012 72 2746 2756 10.1158/0008-5472.CAN-11-1272 22593198 
161. Bellone M.  Calcinotto A.  Filipazzi P.  De Milito A.  Fais S.  Rivoltini L.   The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors Oncoimmunology 2013 2 e22058 10.4161/onci.22058 23483769 
162. Hashim A.A.I.  Abrahams D.  Xu L.  Centeno B.  Sunassee E.  Abddelgader R.  Dubois L.  Lambin P.  Gatenby R.A.  Gillies R.J.   Targeting tumor acidity with the LDHA inhibitor (FX11) and CAIX inhibitor (DH348) overcomes resistance to PD-1 blockade and inhibits metastasis in a pancreatic cancer model Cancer Res. 2017 5932 10.1158/1538-7445.AM2017-5932 
163. Gerweck L.E.  Vijayappa S.  Kozin S.   Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics Mol. Cancer Ther. 2006 5 1275 1279 10.1158/1535-7163.MCT-06-0024 16731760 
164. Logozzi M.  Spugnini E.  Mizzoni D.  Di Raimo R.  Fais S.   Extracellular acidity and increased exosome release as key phenotypes of malignant tumors Cancer Metastasis Rev. 2019 38 93 101 10.1007/s10555-019-09783-8 30715644 
165. Orlowski J.   Heterologous expression and functional properties of amiloride high affinity (NHE-1) and low affinity (NHE-3) isoforms of the rat Na/H exchanger J. Biol. Chem. 1993 268 16369 16377 8393860 
166. Harris C.  Fliegel L.   Amiloride and the Na (+)/H (+) exchanger protein: Mechanism and significance of inhibition of the Na (+)/H (+) exchanger Int. J. Mol. Med. 1999 3 315 336 10.3892/ijmm.3.3.315 10028059 
167. Wang P.  Li L.  Zhang Z.  Kan Q.  Gao F.  Chen S.   Time-dependent activity of Na+/H+ exchanger isoform 1 and homeostasis of intracellular pH in astrocytes exposed to CoCl2  treatment Mol. Med. Rep. 2016 13 4443 4450 10.3892/mmr.2016.5067 27035646 
168. Yang X.  Wang D.  Dong W.  Song Z.  Dou K.   Suppression of Na+/H+ exchanger 1 by RNA interference or amiloride inhibits human hepatoma cell line SMMC-7721 cell invasion Med. Oncol. 2011 28 385 390 10.1007/s12032-010-9447-x 20151228 
169. Guan B.  Hoque A.  Xu X.   Amiloride and guggulsterone suppression of esophageal cancer cell growth in vitro and in nude mouse xenografts Front. Biol. 2014 9 75 81 10.1007/s11515-014-1289-z 
170. Hegde M.  Roscoe J.  Cala P.  Gorin F.   Amiloride kills malignant glioma cells independent of its inhibition of the sodium-hydrogen exchanger J. Pharmacol. Exp. Ther. 2004 310 67 74 10.1124/jpet.103.065029 15010500 
171. Matthews H.  Ranson M.  Kelso M.J.   Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty? Int. J. Cancer 2011 129 2051 2061 10.1002/ijc.26156 21544803 
172. Provost J.J.  Wallert M.A.   Inside out: Targeting NHE1 as an intracellular and extracellular regulator of cancer progression Chem. Biol. Drug Des. 2013 81 85 101 10.1111/cbdd.12035 23253131 
173. Jankun J.  Skrzypczak-Jankun E.   Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride Cancer Biochem. Biophys. 1999 17 109 123 10738907 
174. Matthews H.  Ranson M.  Tyndall J.D.  Kelso M.J.   Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA) Bioorg. Med. Chem. Lett. 2011 21 6760 6766 10.1016/j.bmcl.2011.09.044 21978672 
175. Fliegel L.   Role of pH Regulatory Proteins and Dysregulation of pH in Prostate Cancer Reviews of Physiology, Biochemistry and Pharmacology Springer Berlin/Heidelberg, Germany 2020 10.1007/112_2020_18 
176. Karmazyn M.   The Role of the Myocardial Sodium-Hydrogen Exchanger in Mediating Ischemic and Reperfusion Injury: From Amiloride to Cariporide a Ann. N. Y. Acad. Sci. 1999 874 326 334 10.1111/j.1749-6632.1999.tb09248.x 10415544 
177. Theroux P.  Chaitman B.R.  Danchin N.  Erhardt L.  Meinertz T.  Schroeder J.S.  Tognoni G.  White H.D.  Willerson J.T.  Jessel A.   Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: Main results of the GUARDIAN trial Circulation 2000 102 3032 3038 10.1161/01.CIR.102.25.3032 11120691 
178. Rupprecht H.J.  Dahl J.V.  Terres W.  Seyfarth K.M.  Richardt G.  Schultheiß H.P.  Buerke M.  Sheehan F.H.  Drexler H.   Cardioprotective effects of the Na+/H+ exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA Circulation 2000 101 2902 2908 10.1161/01.CIR.101.25.2902 10869261 
179. Boyce S.W.  Bartels C.  Bolli R.  Chaitman B.  Chen J.C.  Chi E.  Jessel A.  Kereiakes D.  Knight J.  Thulin L.    Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: Results of the CABG surgery cohort of the GUARDIAN study J. Thorac. Cardiovasc. Surg. 2003 126 420 427 10.1016/S0022-5223(03)00209-5 12928639 
180. Wong P.   The Potential of Two New Inhibitors of Mechanisms that Regulate Intracellular Ph, Cariporide And S3705, to Inhibit Tumour Cell Proliferation Ph.D. Thesis University of Toronto National Library of Canada = Bibliothèque Nationale du Canada Toronto, ON, Canada 2001 Available online: https://tspace.library.utoronto.ca/bitstream/1807/15382/1/MQ63113.pdf  (accessed on 1 December 2020) 
181. Di Sario A.  Bendia E.  Omenetti A.  De Minicis S.  Marzioni M.  Kleemann H.W.  Candelaresi C.  Saccomanno S.  Alpini G.  Benedetti A.   Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptosis in cholangiocarcinoma cells Dig. Liver Dis. 2007 39 60 69 10.1016/j.dld.2006.07.013 16982221 
182. Li Q.H.  Lu Y.  Ma L.  Li B.  Yuan W.S.  Ru Y.X.  Wang J.X.  Pang T.X.   Effect of Cariporide on P-glycoprotein to Reverse Multidrug Resistance in K562/DOX Cells Chin. Pharm. J. 2010 10 Available online: http://en.cnki.com.cn/Article_en/CJFDTotal-ZGYX201010009.htm  (accessed on 1 December 2020) 
183. Gao W.  Chang G.  Wang J.  Jin W.  Wang L.  Lin Y.  Li H.  Li M.  Li Q.  Pang T.   Inhibition of K562 leukemia angiogenesis and growth by selective Na+/H+ exchanger inhibitor cariporide through down-regulation of pro-angiogenesis factor VEGF Leuk. Res. 2011 35 1506 1511 10.1016/j.leukres.2011.07.001 21784521 
184. Lin Y.  Chang G.  Wang J.  Jin W.  Wang L.  Li H.  Li M.  Li Q.  Pang T.   NHE1 mediates MDA-MB-231 cells invasion through the regulation of MT1-MMP Exp. Cell Res. 2011 317 2031 2040 10.1016/j.yexcr.2011.05.026 21669197 
185. Lv C.  Yang X.  Yu B.  Ma Q.  Liu B.  Liu Y.   Blocking the Na+/H+ exchanger 1 with cariporide (HOE642) reduces the hypoxia-induced invasion of human tongue squamous cell carcinoma Int. J. Oral Maxillofac. Surg. 2012 41 1206 1210 10.1016/j.ijom.2012.03.001 22464850 
186. Harguindey S.  Arranz J.L.  Orozco JD P.  Rauch C.  Fais S.  Cardone R.A.  Reshkin S.J.   Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs–an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research J. Transl. Med. 2013 11 282 10.1186/1479-5876-11-282 24195657 
187. Chen Q.  Liu Y.  Zhu X.L.  Feng F.  Yang H.  Xu W.   Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo BMC Cancer 2019 19 1 13 10.1186/s12885-019-5397-7 30606139 
188. Li H.  Chang G.  Wang J.  Wang L.  Jin W.  Lin Y.  Yan Y.  Wang R.  Gao W.  Ma L.    Cariporide sensitizes leukemic cells to tumor necrosis factor related apoptosis-inducing ligand by up-regulation of death receptor 5 via endoplasmic reticulum stress–CCAAT/enhancer binding protein homologous protein dependent mechanism Leuk. Lymphoma 2014 55 2135 2140 10.3109/10428194.2013.861064 24188478 
189. Lee Y.J.  Bae J.H.  Kim S.A.  Kim S.H.  Woo K.M.  Nam H.S.  Cho M.K.  Lee S.H.   Cariporide enhances the DNA damage and apoptosis in acid-tolerable malignant mesothelioma H-2452 cells Mol. Cells 2017 40 567 10.14348/molcells.2017.0059 28835017 
190. Albatany M.  Li A.  Meakin S.  Bartha R.   In vivo detection of acute intracellular acidification in glioblastoma multiforme following a single dose of cariporide Int. J. Clin. Oncol. 2018 23 812 819 10.1007/s10147-018-1289-0 29749579 
191. Yang M.  Kozminski D.J.  Wold L.A.  Modak R.  Calhoun J.D.  Isom L.L.  Brackenbury W.J.   Therapeutic potential for phenytoin: Targeting Na v 1.5 sodium channels to reduce migration and invasion in metastatic breast cancer Breast Cancer Res. Treat. 2012 134 603 615 10.1007/s10549-012-2102-9 22678159 
192. Nelson M.  Yang M.  Dowle A.A.  Thomas J.R.  Brackenbury W.J.   The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis Mol. Cancer 2015 14 13 10.1186/s12943-014-0277-x 25623198 
193. Hesselink J.M.K.   Phenytoin: A step by step insight into its multiple mechanisms of action—80 years of mechanistic studies in neuropharmacology J. Neurol. 2017 264 2043 2047 10.1007/s00415-017-8465-4 28349209 
194. Sun G.C.  Werkman T.R.  Wadman W.J.   Kinetic changes and modulation by carbamazepine on voltage-gated sodium channels in rat CA1 neurons after epilepsy Acta Pharmacol. Sin. 2006 27 1537 1546 10.1111/j.1745-7254.2006.00452.x 17112406 
195. Meng Q.  Chen X.  Sun L.  Zhao C.  Sui G.  Cai L.   Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90 Mol. Cell. Biochem. 2011 348 165 171 10.1007/s11010-010-0651-y 21082217 
196. Meng Q.W.  Zhao C.H.  Xi Y.H.  Cai L.  Sun L.C.  Sui G.J.   Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells Chin. J. Cancer 2006 25 967 973 
197. Abdul M.  Hoosein N.   Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells Anticancer Res. 2001 21 2045 11497296 
198. Pellegrino M.  Rizza P.  Nigro A.  Ceraldi R.  Ricci E.  Perrotta I.  Aquila S.  Lanzino M.  Andò S.  Morelli C.    FoxO3a mediates the inhibitory effects of the antiepileptic drug Lamotrigine on breast cancer growth Mol. Cancer Res. 2018 16 923 934 10.1158/1541-7786.MCR-17-0662 29523760 
199. Xu G.  Fang Z.  Clark L.H.  Sun W.  Yin Y.  Zhang R.  Sullivan S.A.  Tran A.Q.  Kong W.  Wang J.    Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells Am. J. Transl. Res. 2018 10 1663 30018708 
200. Ma B.  Pan Y.  Song Q.  Tie L.  Zhang Y.  Xiao Y.  Zhang J.  Han J.  Xu Y.  Xiang Y.    The effect of topiramate on tumor-related angiogenesis and on the serum proteome of mice bearing Lewis lung carcinoma Eur. J. Pharmacol. 2011 663 9 16 10.1016/j.ejphar.2011.04.056 21596032 
201. Ma B.  Xiang Y.  Li T.  Yu H.M.  Li X.J.   Inhibitory effect of topiramate on Lewis lung carcinoma metastasis and its relation with AQP1 water channel Acta Pharm. Sin 2004 25 54 60 
202. Tran AQ M.  Sullivan S.A.  Xu G.  Zhou C.  Bae-Jump V.L.   Repurposing topiramate as a novel targeted therapy for ovarian cancer Gynecol. Oncol. 2017 145 108 10.1016/j.ygyno.2017.03.255 28196673 
203. Koltai T.   Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs F1000Research 2015 4 297 10.12688/f1000research.6789.1 27408684 
204. Rogawski M.A.  Löscher W.   The neurobiology of antiepileptic drugs Nat. Rev. Neurosci. 2004 5 553 564 10.1038/nrn1430 15208697 
205. Marathe K.  McVicar N.  Li A.  Bellyou M.  Meakin S.  Bartha R.   Topiramate induces acute intracellular acidification in glioblastoma J. Neuro-Oncol. 2016 130 465 472 10.1007/s11060-016-2258-y 
206. Dodgson S.J.  Shank R.P.  Maryanoff B.E.   Topiramate as an inhibitor of carbonic anhydrase isoenzymes Epilepsia 2000 41 35 39 10.1111/j.1528-1157.2000.tb02169.x 10768298 
207. Maryanoff B.E.  McComsey D.F.  Costanzo M.J.  Hochman C.  Smith-Swintosky V.  Shank R.P.   Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform J. Med. Chem. 2005 48 1941 1947 10.1021/jm040124c 15771438 
208. Huber V.J.  Tsujita M.  Kwee I.L.  Nakada T.   Inhibition of aquaporin 4 by antiepileptic drugs Bioorg. Med. Chem. 2009 17 418 424 10.1016/j.bmc.2007.12.038 18178093 
209. Ma L.  Huang Y.G.  Deng Y.C.  Tian J.Y.  Rao Z.R.  Che H.L.  Zhang H.F.  Zhao G.   Topiramate reduced sweat secretion and aquaporin-5 expression in sweat glands of mice Life Sci. 2007 80 2461 2468 10.1016/j.lfs.2007.04.018 17521680 
210. Nico B.  Ribatti D.   Aquaporins in tumor growth and angiogenesis Cancer Lett. 2010 294 135 138 10.1016/j.canlet.2010.02.005 20199845 
211. Ribatti D.  Ranieri G.  Annese T.  Nico B.   Aquaporins in cancer Biochim. Biophys. Acta (BBA)-Gen. Subj. 2014 1840 1550 1553 10.1016/j.bbagen.2013.09.025 
212. Otterbach F.  Callies R.  Adamzik M.  Kimmig R.  Siffert W.  Schmid K.W.  Bankfalvi A.   Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas Breast Cancer Res. Treat. 2010 120 67 76 10.1007/s10549-009-0370-9 19306058 
213. Wang L.  Zhang Y.  Wu X.  Yu G.   Aquaporins: New targets for cancer therapy Technol. Cancer Res. Treat. 2016 15 821 828 10.1177/1533034615607693 26438607 
214. Luo L.M.  Xia H.  Shi R.  Zeng J.  Liu X.R.  Wei M.   The association between aquaporin-1 expression, microvessel density and the clinicopathological features of hepatocellular carcinoma Oncol. Lett. 2017 14 7077 7084 10.3892/ol.2017.7106 29344137 
215. Rothert M.  Rönfeldt D.  Beitz E.   Electrostatic attraction of weak monoacid anions increases probability for protonation and passage through aquaporins J. Biol. Chem. 2017 292 9358 9364 10.1074/jbc.M117.782516 28360107 
216. Li H.  Chen H.  Steinbronn C.  Wu B.  Beitz E.  Zeuthen T.  Voth G.A.   Enhancement of proton conductance by mutations of the selectivity filter of aquaporin-1 J. Mol. Biol. 2011 407 607 620 10.1016/j.jmb.2011.01.036 21277313 
217. Yasui M.  Hazama A.  Kwon T.H.  Nielsen S.  Guggino W.B.  Agre P.   Rapid gating and anion permeability of an intracellular aquaporin Nature 1999 402 184 187 10.1038/46045 10647010 
218. Nico B.  Ribatti D.   Role of aquaporins in cell migration and edema formation in human brain tumors Exp. Cell Res. 2011 317 2391 2396 10.1016/j.yexcr.2011.07.006 21784068 
219. Yool A.J.  Brown E.A.  Flynn G.A.   Roles for novel pharmacological blockers of aquaporins in the treatment of brain oedema and cancer Clin. Exp. Pharmacol. Physiol. 2010 37 403 409 10.1111/j.1440-1681.2009.05244.x 19566827 
220. Li X.  Alvarez B.  Casey J.R.  Reithmeier R.A.  Fliegel L.   Carbonic anhydrase II binds to and enhances activity of the Na+/H+ exchanger J. Biol. Chem. 2002 277 36085 36091 10.1074/jbc.M111952200 12138085 
221. Li X.  Liu Y.  Alvarez B.V.  Casey J.R.  Fliegel L.   A novel carbonic anhydrase II binding site regulates NHE1 activity Biochemistry 2006 45 2414 2424 10.1021/bi051132d 16475831 
222. Noor S.I.  Jamali S.  Ames S.  Langer S.  Deitmer J.W.  Becker H.M.   A surface proton antenna in carbonic anhydrase II supports lactate transport in cancer cells Elife 2018 7 e35176 10.7554/eLife.35176 29809145 
223. Yoshiura K.  Nakaoka T.  Nishishita T.  Sato K.  Yamamoto A.  Shimada S.  Saida T.  Kawakami Y.  Takahashi T.A.  Fukuda H.    Carbonic anhydrase II is a tumor vessel endothelium–associated antigen targeted by dendritic cell therapy Clin. Cancer Res. 2005 11 8201 8207 10.1158/1078-0432.CCR-05-0816 16299253 
224. Parkkila S.  Rajaniemi H.  Parkkila A.K.  Kivelä J.  Waheed A.  Pastoreková S.  Pastorek J.  Sly W.S.   Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro Proc. Natl. Acad. Sci. USA 2000 97 2220 2224 10.1073/pnas.040554897 10688890 
225. Haapasalo J.  Nordfors K.  Järvelä S.  Bragge H.  Rantala I.  Parkkila A.K.  Haapasalo H.  Parkkila S.   Carbonic anhydrase II in the endothelium of glial tumors: A potential target for therapy Neuro Oncol. 2007 9 308 313 10.1215/15228517-2007-001 17435181 
226. Leppilampi M.  Koistinen P.  Savolainen E.R.  Hannuksela J.  Parkkila A.K.  Niemelä O.  Pastoreková S.  Pastorek J.  Waheed A.  Sly W.S.    The expression of carbonic anhydrase II in hematological malignancies Clin. Cancer Res. 2002 8 2240 2245 12114426 
227. Lankat-Buttgereit B.  Gregel C.  Knolle A.  Hasilik A.  Arnold R.  Göke R.   Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II Mol. Cell. Endocrinol. 2004 214 149 153 10.1016/j.mce.2003.10.058 15062553 
228. Meldrum N.U.  Roughton F.J.W.   Carbonic anhydrase. Its preparation and properties J. Physiol. 1933 80 113 142 10.1113/jphysiol.1933.sp003077 16994489 
229. Schwartz W.B.   The effect of sulfanilamide on salt and water excretion in congestive heart failure N. Engl. J. Med. 1949 240 173 177 10.1056/NEJM194902032400503 18108079 
230. Korhonen K.  Parkkila A.K.  Helen P.  Välimäki R.  Pastorekova S.  Pastorek J.  Parkkila S.  Haapasalo H.   Carbonic anhydrases in meningiomas: Association of endothelial carbonic anhydrase II with aggressive tumor features J. Neurosurg. 2009 111 472 477 10.3171/2008.10.17672 19216648 
231. Kivelã A.J.  Saarnio J.  Karttunen T.J.  Kivelã J.  Parkkila A.K.  Pastorekova S.  Pastorek J.  Waheed A.  Sly W.S.  Parkkila S.    Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors Dig. Dis. Sci. 2001 46 2179 2186 10.1023/A:1011910931210 11680594 
232. Mboge M.Y.  Kota A.  McKenna R.  Frost S.C.   Biophysical, Biochemical, and Cell Based Approaches Used to Decipher the Role of Carbonic Anhydrases in Cancer and to Evaluate the Potency of Targeted Inhibitors Int. J. Med. Chem. 2018 2018 10.1155/2018/2906519 
233. Mahieu I.  Becq F.  Wolfensberger T.  Gola M.  Carter N.  Hollande E.   The expression of carbonic anhydrases II and IV in the human pancreatic cancer cell line (Capan 1) is associated with bicarbonate ion channels Biol. Cell 1994 81 131 141 10.1016/S0248-4900(94)80004-9 7531530 
234. Bootorabi F.  Haapasalo J.  Smith E.  Haapasalo H.  Parkkila S.   Carbonic anhydrase VII–a potential prognostic marker in gliomas Health 2011 3 6 10.4236/health.2011.31002 
235. Fais S.  De Milito A.  You H.  Qin W.   Targeting vacuolar H+-ATPases as a new strategy against cancer Cancer Res. 2007 67 10627 10630 10.1158/0008-5472.CAN-07-1805 18006801 
236. Taylor S.  Spugnini E.P.  Assaraf Y.G.  Azzarito T.  Rauch C.  Fais S.   Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach Drug Resist. Updates 2015 23 69 78 10.1016/j.drup.2015.08.004 
237. Ferrari S.  Perut F.  Fagioli F.  Del Prever A.B.  Meazza C.  Parafioriti A.  Picci P.  Gambarotti M.  Avnet M.  Baldini N.    Proton pump inhibitor chemosensitization in human osteosarcoma: From the bench to the patients’ bed J. Transl. Med. 2013 11 1 7 10.1186/1479-5876-11-268 23281771 
238. Wang B.Y.  Zhang J.  Wang J.L.  Sun S.  Wang Z.H.  Wang L.P.  Zhang Q.L.  Lv F.F.  Cao E.Y.  Shao Z.M.    Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer J. Exp. Clin. Cancer Res. 2015 34 85 10.1186/s13046-015-0194-x 26297142 
239. Tanigawa T.  Watanabe T.  Higuchi K.  Machida H.  Okazaki H.  Yamagami H.  Watanabe K.  Tominaga K.  Fujiwara Y.  Oshitani N.    Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-α and interleukin-1β induced by lipopolysaccharide and Helicobacter Pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-κB and extracellular signal-regulated kinase J. Clin. Biochem. Nutr. 2009 45 86 92 19590712 
240. Ohta T.  Tajima H.  Yachie A.  Yokoyama K.  Elnemr A.  Fushida S.  Kitagawa H.  Kayahara M.  Nishimura G.  Miwa K.    Yamamoto, M. Activated lansoprazole inhibits cancer cell adhesion to extracellular matrix components Int. J. Oncol. 1999 15 33 42 10375591 
241. Spugnini E.P.  Buglioni S.  Carocci F.  Francesco M.  Vincenzi B.  Fanciulli M.  Fais S.   High dose lansoprazole combined with metronomic chemotherapy: A phase I/II study in companion animals with spontaneously occurring tumors J. Transl. Med. 2014 12 225 10.1186/s12967-014-0225-y 25143012 
242. Federici C.  Lugini L.  Marino M.L.  Carta F.  Iessi E.  Azzarito T.  Supuran C.T.  Fais S.   Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells J. Enzym. Inhib. Med. Chem. 2016 31 119 125 10.1080/14756366.2016.1177525 
243. Ihraiz W.G.  Ahram M.  Bardaweel S.K.   Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells Acta Pharm. 2020 70 179 190 10.2478/acph-2020-0020 31955147 
244. Zhang S.  Wang Y.  Li S.J.   Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion Biochem. Biophys. Res. Commun. 2014 448 424 429 10.1016/j.bbrc.2014.04.127 24802401 
245. Fako V.E.  Wu X.  Pflug B.  Liu J.Y.  Zhang J.T.   Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase J. Med. Chem. 2015 58 778 784 10.1021/jm501543u 25513712 
246. Murakami A.  Ashida H.  Terao J.   Multitargeted cancer prevention by quercetin Cancer Lett. 2008 269 315 325 10.1016/j.canlet.2008.03.046 18467024 
247. Jeong J.H.  An J.Y.  Kwon Y.T.  Rhee J.G.  Lee Y.J.   Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression J. Cell. Biochem. 2009 106 73 82 10.1002/jcb.21977 19009557 
248. Yoshida M.  Sakai T.  Hosokawa N.  Marui N.  Matsumoto K.  Fujioka A.  Nishino H.  Aoike A.   The effect of quercetin on cell cycle progression and growth of human gastric cancer cells FEBS Lett. 1990 260 10 13 10.1016/0014-5793(90)80053-L 2298289 
249. Choi J.A.  Kim J.Y.  Lee J.Y.  Kang C.M.  Kwon H.J.  Yoo Y.D.  Kim T.W.  Lee Y.S.  Lee S.J.   Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin Int. J. Oncol. 2001 19 837 844 10.3892/ijo.19.4.837 11562764 
250. Gibellini L.  Pinti M.  Nasi M.  De Biasi S.  Roat E.  Bertoncelli L.  Cossarizza A.   Interfering with ROS metabolism in cancer cells: The potential role of quercetin Cancers 2010 2 1288 1311 10.3390/cancers2021288 24281116 
251. Xing N.  Chen Y.  Mitchell S.H.  Young C.Y.   Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells Carcinogenesis 2001 22 409 414 10.1093/carcin/22.3.409 11238180 
252. Zhou W.  Kallifatidis G.  Baumann B.  Rausch V.  Mattern J.  Gladkich J.  Giese N.  Moldenhauer G.  Wirth T.  Büchler M.W.    Dietary polyphenol quercetin targets pancreatic cancer stem cells Int. J. Oncol. 2010 37 551 561 20664924 
253. Avila M.A.  Velasco J.A.  Cansado J.  Notario V.   Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468 Cancer Res. 1994 54 2424 2428 8162591 
254. Vijayababu M.R.  Arunkumar A.  Kanagaraj P.  Venkataraman P.  Krishnamoorthy G.  Arunakaran J.   Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3) Mol. Cell. Biochem. 2006 287 109 116 10.1007/s11010-005-9085-3 16645725 
255. Ranelletti F.O.  Maggiano N.  Serra F.G.  Ricci R.  Larocca L.M.  Lanza P.  Scambia G.  Fattorossi A.  Capelli A.  Piantelli M.   Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors Int. J. Cancer 2000 85 438 445 10.1002/(SICI)1097-0215(20000201)85:3<438::AID-IJC22>3.0.CO;2-F 10652438 
256. Harris D.M.  Li L.  Chen M.  Lagunero F.T.  Go V.L.W.  Boros L.G.   Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: A comparative glucose tracer study with the fatty acid synthase inhibitor C75 Metabolomics 2012 8 201 210 10.1007/s11306-011-0300-9 22754424 
257. Loke W.M.  Proudfoot J.M.  Stewart S.  McKinley A.J.  Needs P.W.  Kroon P.A.  Hodgson J.M.  Croft K.D.   Metabolic transformation has a profound effect on anti-inflammatory activity of flavonoids such as quercetin: Lack of association between antioxidant and lipoxygenase inhibitory activity Biochem. Pharmacol. 2008 75 1045 1053 10.1016/j.bcp.2007.11.002 18096136 
258. Sang D.P.  Li R.J.  Lan Q.   Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27 Acta Pharmacol. Sin. 2014 35 832 838 10.1038/aps.2014.22 24902789 
259. Granato M.  Rizzello C.  Romeo M.A.  Yadav S.  Santarelli R.  D’Orazi G.  Faggioni A.  Cirone M.   Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt’s lymphoma Int. J. Biochem. Cell Biol. 2016 79 393 400 10.1016/j.biocel.2016.09.006 27620077 
260. Damiano F.  Giannotti L.  Gnoni G.V.  Siculella L.  Gnoni A.   Quercetin inhibition of SREBPs and ChREBP expression results in reduced cholesterol and fatty acid synthesis in C6 glioma cells Int. J. Biochem. Cell Biol. 2019 117 105618 10.1016/j.biocel.2019.105618 31542428 
261. Reyes-Farias M.  Carrasco-Pozo C.   The anti-cancer effect of quercetin: Molecular implications in cancer metabolism Int. J. Mol. Sci. 2019 20 3177 10.3390/ijms20133177 
262. Tavana E.  Mollazadeh H.  Mohtashami E.  Modaresi SM S.  Hosseini A.  Sabri H.  Soltani A.  Javid H.  Afshari A.R.  Sahebkar A.   Quercetin: A promising phytochemical for the treatment of glioblastoma multiforme BioFactors 2020 46 356 366 10.1002/biof.1605 31880372 
263. Volk C.  Kempski B.  Kempski O.S.   Inhibition of lactate export by quercetin acidifies rat glial cells in vitro Neurosci. Lett. 1997 223 121 124 10.1016/S0304-3940(97)13420-6 9089688 
264. Kim J.H.  Kim S.H.  Alfieri A.A.  Young C.W.   Quercetin, an inhibitor of lactate transport and a hyperthermic sensitizer of HeLa cells Cancer Res. 1984 44 102 106 6690027 
265. Albatany M.  Meakin S.  Bartha R.   The Monocarboxylate transporter inhibitor quercetin induces intracellular acidification in a mouse model of glioblastoma multiforme: In-vivo detection using magnetic resonance imaging Investig. New Drugs 2019 37 595 601 10.1007/s10637-018-0644-3 30101388 
266. Amorim R.  Pinheiro C.  Miranda-Gonçalves V.  Pereira H.  Moyer M.P.  Preto A.  Baltazar F.   Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells Cancer Lett. 2015 365 68 78 10.1016/j.canlet.2015.05.015 26021766 
267. Maso V.  Calgarotto A.K.  Franchi G.C.  Nowill A.E.  Latuf Filho P.  Vassallo J.  Saad S.T.O.   Multitarget effects of quercetin in leukemia Cancer Prev. Res. 2014 7 1240 1250 10.1158/1940-6207.CAPR-13-0383 
268. Belt J.A.  Thomas J.A.  Buchsbaum R.N.  Racker E.   Inhibition of lactate transport and glycolysis in Ehrlich ascites tumor cells by bioflavonoids Biochemistry 1979 18 3506 3511 10.1021/bi00583a011 38832 
269. Wenzel U.  Kuntz S.  Daniel H.   Flavonoids with epidermal growth factor-receptor tyrosine kinase inhibitory activity stimulate PEPT1-mediated cefixime uptake into human intestinal epithelial cells J. Pharmacol. Exp. Ther. 2001 299 351 357 11561098 
270. Nakajima K.I.  Niisato N.  Marunaka Y.   Quercetin stimulates NGF-induced neurite outgrowth in PC12 cells via activation of Na+/K+/2Cl-cotransporter Cell. Physiol. Biochem. 2011 28 147 156 10.1159/000331723 21865857 
271. Sturza A.  Pavel I.  Ancușa S.  Danciu C.  Dehelean C.  Duicu O.  Muntean D.   Quercetin exerts an inhibitory effect on cellular bioenergetics of the B164A5 murine melanoma cell line Mol. Cell. Biochem. 2018 447 103 109 10.1007/s11010-018-3296-x 29380243 
272. Harwood M.  Danielewska-Nikiel B.  Borzelleca J.F.  Flamm G.W.  Williams G.M.  Lines T.C.   A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties Food Chem. Toxicol. 2007 45 2179 2205 10.1016/j.fct.2007.05.015 17698276 
273. Ambrose A.M.  Robbins D.J.  Deeds F.   Comparative toxicities of quercetin and quercitrin J. Am. Pharm. Assoc. (Sci. Ed.) 1952 41 119 122 10.1002/jps.3030410303 
274. Van der Hoeven J.C.M.  Bruggeman I.M.  Debets F.M.H.   Genotoxicity of quercetin in cultured mammalian cells Mutat. Res. Genet. Toxicol. 1984 136 9 21 10.1016/0165-1218(84)90130-7 
275. Indap M.A.  Bhosle S.C.  Tayade P.T.  Vavia P.R.   Evaluation of Toxicity And Antitumour Effects Of A Hydroxypropyl?-Cyclodextrin Inclusion Complex Of Quercetin Indian J. Pharm. Sci. 2002 64 349 
276. Ferry D.R.  Smith A.  Malkhandi J.  Fyfe D.W.  de Takats P.G.  Anderson D.  Baker J.  Kerr D.J.   Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition Clin. Cancer Res. 1996 2 659 668 9816216 
277. Hollman P.C.  de Vries J.H.  van Leeuwen S.D.  Mengelers M.J.  Katan M.B.   Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers Am. J. Clin. Nutr. 1995 62 1276 1282 10.1093/ajcn/62.6.1276 7491892 
278. Erlund I.  Kosonen T.  Alfthan G.  Mäenpää J.  Perttunen K.  Kenraali J.  Parantainen J.  Aro A.   Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers Eur. J. Clin. Pharmacol. 2000 56 545 553 10.1007/s002280000197 11151743 
279. Olthof M.R.  Hollman P.C.  Vree T.B.  Katan M.B.   Bioavailabilities of quercetin-3-glucoside and quercetin-4′-glucoside do not differ in humans J. Nutr. 2000 130 1200 1203 10.1093/jn/130.5.1200 10801919 
280. Hubbard G.P.  Wolffram S.  Lovegrove J.A.  Gibbins J.M.   Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans J. Thromb. Haemost. 2004 2 2138 2145 10.1111/j.1538-7836.2004.01067.x 15613018 
281. Boots A.W.  Wilms L.C.  Swennen E.L.  Kleinjans J.C.  Bast A.  Haenen G.R.   In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers Nutrition 2008 24 703 710 10.1016/j.nut.2008.03.023 18549926 
282. Egert S.  Wolffram S.  Bosy-Westphal A.  Boesch-Saadatmandi C.  Wagner A.E.  Frank J.  Rimbach G.  Mueller M.J.   Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans J. Nutr. 2008 138 1615 1621 10.1093/jn/138.9.1615 18716159 
283. Kobayashi M.  Otsuka Y.  Itagaki S.  Hirano T.  Iseki K.   Inhibitory effects of statins on human monocarboxylate transporter 4 Int. J. Pharm. 2006 317 19 25 10.1016/j.ijpharm.2006.02.043 16621368 
284. Mehibel M.  Ortiz-Martinez F.  Voelxen N.  Boyers A.  Chadwick A.  Telfer B.A.  Mueller-Klieser W.  West C.M.  Critchlow S.E.  Williams K.J.    Statin-induced metabolic reprogramming in head and neck cancer: A biomarker for targeting monocarboxylate transporters Sci. Rep. 2018 8 1 12 10.1038/s41598-018-35103-1 29311619 
285. Kikutani Y.  Kobayashi M.  Konishi T.  Sasaki S.  Narumi K.  Furugen A.  Takahashi N.  Iseki K.   Involvement of monocarboxylate transporter 4 expression in statin-induced cytotoxicity J. Pharm. Sci. 2016 105 1544 1549 10.1016/j.xphs.2016.01.014 26935883 
286. du Souich P.  Roederer G.  Dufour R.   Myotoxicity of statins: Mechanism of action Pharmacol. Ther. 2017 175 1 16 10.1016/j.pharmthera.2017.02.029 28223230 
287. Cermak R.  Wein S.  Wolffram S.  Langguth P.   Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs Eur. J. Pharm. Sci. 2009 38 519 524 10.1016/j.ejps.2009.09.018 19804821 
288. Evans J.M.  Donnelly L.A.  Emslie-Smith A.M.  Alessi D.R.  Morris A.D.   Metformin and reduced risk of cancer in diabetic patients BMJ 2005 330 1304 1305 10.1136/bmj.38415.708634.F7 15849206 
289. DeCensi A.  Puntoni M.  Goodwin P.  Cazzaniga M.  Gennari A.  Bonanni B.  Gandini S.   Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis Cancer Prev. Res. 2010 3 1451 1461 10.1158/1940-6207.CAPR-10-0157 
290. Noto H.  Goto A.  Tsujimoto T.  Noda M.   Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis PLoS ONE 2012 7 e33411 10.1371/journal.pone.0033411 22448244 
291. Gandini S.  Puntoni M.  Heckman-Stoddard B.M.  Dunn B.K.  Ford L.  DeCensi A.  Szabo E.   Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders Cancer Prev. Res. 2014 7 867 885 10.1158/1940-6207.CAPR-13-0424 
292. Suissa S.  Azoulay L.   Metformin and the risk of cancer: Time-related biases in observational studies Diabetes Care 2012 35 2665 2673 10.2337/dc12-0788 23173135 
293. Kasznicki J.  Sliwinska A.  Drzewoski J.   Metformin in cancer prevention and therapy Ann. Transl. Med. 2014 2 57 25333032 
294. Rena G.  Hardie D.G.  Pearson E.R.   The mechanisms of action of metformin Diabetologia 2017 60 1577 1585 10.1007/s00125-017-4342-z 28776086 
295. Vancura A.  Bu P.  Bhagwat M.  Zeng J.  Vancurova I.   Metformin as an anticancer agent Trends Pharmacol. Sci. 2018 39 867 878 10.1016/j.tips.2018.07.006 30150001 
296. Owen M.R.  Doran E.  Halestrap A.P.   Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain Biochem. J. 2000 348 607 614 10.1042/bj3480607 10839993 
297. Wheaton W.W.  Weinberg S.E.  Hamanaka R.B.  Soberanes S.  Sullivan L.B.  Anso E.  Glasauer A.  Dufour E.  Mutlu G.M.  Budigner G.S.    Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis elife 2014 3 e02242 10.7554/eLife.02242 24843020 
298. Brunmair B.  Staniek K.  Gras F.  Scharf N.  Althaym A.  Clara R.  Roden M.  Gnaiger E.  Nohl H.  Waldhäusl W.    Thiazolidinediones, like metformin, inhibit respiratory complex I: A common mechanism contributing to their antidiabetic actions? Diabetes 2004 53 1052 1059 10.2337/diabetes.53.4.1052 15047621 
299. Cameron A.R.  Logie L.  Patel K.  Erhardt S.  Bacon S.  Middleton P.  Harthill J.  Forteath C.  Coats J.T.  Kerr C.    Metformin selectively targets redox control of complex I energy transduction Redox Biol. 2018 14 187 197 10.1016/j.redox.2017.08.018 28942196 
300. Gui D.Y.  Sullivan L.B.  Luengo A.  Hosios A.M.  Bush L.N.  Gitego N.  Davidson S.M.  Freinkman E.  Thomas J.  Vander Heiden M.G.   Environment dictates dependence on mitochondrial complex I for NAD+ and aspartate production and determines cancer cell sensitivity to metformin Cell Metab. 2016 24 716 727 10.1016/j.cmet.2016.09.006 27746050 
301. Fontaine E.   Metformin-induced mitochondrial complex I inhibition: Facts, uncertainties, and consequences Front. Endocrinol. 2018 9 753 10.3389/fendo.2018.00753 
302. Luengo A.  Sullivan L.B.  Vander Heiden M.G.   Understanding the complex-I-ty of metformin action: Limiting mitochondrial respiration to improve cancer therapy BMC Biol. 2014 12 1 4 10.1186/s12915-014-0082-4 24417977 
303. Pernicova I.  Korbonits M.   Metformin—mode of action and clinical implications for diabetes and cancer Nat. Rev. Endocrinol. 2014 10 143 10.1038/nrendo.2013.256 24393785 
304. Lalau J.D.   Lactic acidosis induced by metformin Drug Saf. 2010 33 727 740 10.2165/11536790-000000000-00000 20701406 
305. Salpeter S.R.  Greyber E.  Pasternak G.A.  Salpeter E.E.   Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst. Rev. 2010 10.1002/14651858.CD002967.pub4 
306. DeFronzo R.  Fleming G.A.  Chen K.  Bicsak T.A.   Metformin-associated lactic acidosis: Current perspectives on causes and risk Metabolism 2016 65 20 29 10.1016/j.metabol.2015.10.014 26773926 
307. Melnik S.  Dvornikov D.  Müller-Decker K.  Depner S.  Stannek P.  Meister M.  Warth A.  Thomas M.  Muley T.  Risch A.    Cancer cell specific inhibition of Wnt/β-catenin signaling by forced intracellular acidification Cell Discov. 2018 4 1 17 10.1038/s41421-018-0033-2 29423269 
308. Albatany M.  Ostapchenko V.G.  Meakin S.  Bartha R.   Brain tumor acidification using drugs simultaneously targeting multiple pH regulatory mechanisms J. Neuro-Oncol. 2019 144 453 462 10.1007/s11060-019-03251-7 
309. Vail D.M.  Macewen E.G.   Spontaneously occurring tumors of companion animals as models for human cancer Cancer Investig. 2000 18 781 792 10.3109/07357900009012210 11107448 
310. Cekanova M.  Rathore K.   Animal models and therapeutic molecular targets of cancer: Utility and limitations Drug Des. Dev. Ther. 2014 8 1911 10.2147/DDDT.S49584 
311. Spugnini E.P.  Baldi A.  Buglioni S.  Carocci F.  de Bazzichini G.M.  Betti G.  Pantaleo I.  Menicagli F.  Citro G.  Fais S.   Lansoprazole as a rescue agent in chemoresistant tumors: A phase I/II study in companion animals with spontaneously occurring tumors J. Transl. Med. 2011 9 221 10.1186/1479-5876-9-221 22204495 
312. Walsh M.  Fais S.  Spugnini E.P.  Harguindey S.  Izneid T.A.  Scacco L.  Williams P.  Allegrucci C.  Rauch C.  Omran Z.   Proton pump inhibitors for the treatment of cancer in companion animals J. Exp. Clin. Cancer Res. 2015 34 93 10.1186/s13046-015-0204-z 26337905 
313. Koltai T.  Cardone R.A.  Reshkin S.J.   Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer Int. J. Mol. Sci. 2019 20 5438 10.3390/ijms20215438 
314. Shim C.K.  Cheon E.P.  Kang K.W.  Seo K.S.  Han H.K.   Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in Caco-2 cells J. Pharm. Pharmacol. 2007 59 1515 1519 10.1211/jpp.59.11.0008 17976262 
315. Li L.  Gao Y.  Zhang L.  Zeng J.  He D.  Sun Y.   Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR–ERK activation in renal cell carcinoma Cancer Lett. 2008 272 61 69 10.1016/j.canlet.2008.06.033 18723275 
316. Cheung C.W.  Taylor P.J.  Kirkpatrick C.M.  Vesey D.A.  Gobe G.C.  Winterford C.  Nicol D.L.  Johnson D.W.   Therapeutic value of orally administered silibinin in renal cell carcinoma: Manipulation of insulin-like growth factor binding protein-3 levels BJU Int. 2007 100 438 444 10.1111/j.1464-410X.2007.07012.x 17617146 
317. Liang L.  Li L.  Zeng J.  Gao Y.  Chen Y.L.  Wang Z.Q.  Wang X.Y.  Chang L.S.  He D.   Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway Oncol. Rep. 2012 28 999 1005 22736024 
318. Youn C.K.  Cho S.I.  Lee M.Y.  Jeon Y.J.  Lee S.K.   Inhibition of ERK1/2 by silymarin in mouse mesangial cells Korean J. Physiol. Pharmacol. 2017 21 117 124 10.4196/kjpp.2017.21.1.117 28066148 
319. Chang H.R.  Chen P.N.  Yang S.F.  Sun Y.S.  Wu S.W.  Hung T.W.  Lian J.D.  Chu S.C.  Hsieh Y.S.   Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel Mol. Carcinog. 2011 50 811 823 10.1002/mc.20756 21574189 
320. Li F.  Ma Z.  Guan Z.  Chen Y.  Wu K.  Guo P.  Wang X.  He D.  Zeng J.   Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma Int. J. Mol. Sci. 2015 16 8415 8429 10.3390/ijms16048415 25884331 
321. Ma Z.  Liu W.  Zeng J.  Zhou J.  Guo P.  Xie H.  Zhao Y.  Zheng L.  Xu S.  Wang X.    Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma Oncol. Rep. 2015 34 2461 2468 10.3892/or.2015.4224 26323996 
322. Cheung C.W.  Vesey D.A.  Nicol D.L.  Johnson D.W.   Silibinin inhibits renal cell carcinoma via mechanisms that are independent of insulin-like growth factor-binding protein 3 BJU Int. 2007 99 454 460 10.1111/j.1464-410X.2007.06571.x 17313429 
323. Fan Y.  Hou T.  Dan W.  Liu T.  Luan J.  Liu B.  Li L.  Zeng J.   Silibinin inhibits epithelial-mesenchymal transition of renal cell carcinoma through autophagy-dependent Wnt/β-catenin signaling Int. J. Mol. Med. 2020 45 1341 1350 10.3892/ijmm.2020.4521 32323735 
324. Yang C.  Li F.  Ma J.  Zhang H.-B.  Jia J.  Zeng J.  Wang X.  He D.  Guo P.   Evaluation of anti-cancer potency of silibinin on murine renal carcinoma RenCa cells in an animal model with an intact immune system Anti-Cancer Drugs 2020 31 785 791 10.1097/CAD.0000000000000931 32209841 
325. Wang X.  He D.   MP92-15 suppression of chaperone-mediated autophagy: A novel mechanism of action of silibinin against bladder and renal cancer J. Urol. 2016 195 e1167 
326. Ma Z.  Zang W.  Wang H.  Wei X.   Silibinin enhances anti-renal fibrosis effect of MK-521 via downregulation of TGF-β signaling pathway Hum. Cell 2020 33 330 336 10.1007/s13577-019-00314-9 31953678 
327. Liu R.  Wang Q.  Ding Z.  Zhang X.  Li Y.  Zang Y.  Zhang G.   Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-βSignaling in Kidney Drug Des. Dev. Ther. 2020 14 603 10.2147/DDDT.S224308 
328. Xu S.  Fan Y.Z.  Ma Z.K.  Yang Z.  Wang K.  Wu K.J.  Wang X.Y.  Zeng J.  Guo P.  He D.L.   Silibinin induces apoptosis by caspase activation, down-regulating Bcl-2 and activating YAP/p53 in renal cell carcinoma Int. J. Clin. Exp. Med. 2016 9 2343 U9595 
329. Wu T.  Liu W.  Guo W.  Zhu X.   Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells Biomed. Pharmacother. 2016 81 460 467 10.1016/j.biopha.2016.04.039 27261626 
330. Mastron J.K.  Siveen K.S.  Sethi G.  Bishayee A.   Silymarin and hepatocellular carcinoma: A systematic, comprehensive, and critical review Anti-Cancer Drugs 2015 26 475 486 10.1097/CAD.0000000000000211 25603021 
331. Choe U.  Whent M.  Luo Y.  Yu L.   Total phenolic content, free radical scavenging capacity, and anti-cancer activity of silymarin J. Food Bioact. 2020 10 53 63 10.31665/JFB.2020.10227 
332. Li F.  Sun Y.  Jia J.  Yang C.  Tang X.  Jin B.  Wang K.  Guo P.  Ma Z.  Chen Y.    Silibinin attenuates TGF-β1-induced migration and invasion via EMT suppression and is associated with COX-2 downregulation in bladder transitional cell carcinoma Oncol. Rep. 2018 40 3543 3550 10.3892/or.2018.6728 30272315 
333. Boojar MM A.  Boojar MM A.  Golmohammad S.   Overview of Silibinin anti-tumor effects J. Herbal Med. 2020 23 100375 10.1016/j.hermed.2020.100375 
334. Moore N.  Houghton J.M.  Lyle S.   Slow-cycling therapy-resistant cancer cells Stem Cells Dev. 2012 21 1822 1830 10.1089/scd.2011.0477 21973238 
335. Kim J.K.  Jung Y.  Wang J.  Joseph J.  Mishra A.  Hill E.E.  Krebsbach P.H.  Pienta K.J.  Shiozawa Y.  Taichman R.S.   TBK1 Regulates Prostate Cancer Dormancy through mTOR Inhibition Neoplasia 2013 15 1064 1074 10.1593/neo.13402 24027431 
336. Jia M.  Zheng D.  Wang X.  Zhang Y.  Chen S.  Cai X.  Mo L.  Hu Z.  Li H.  Zhou Z.    Cancer Cell enters reversible quiescence through Intracellular Acidification to resist Paclitaxel Cytotoxicity Int. J. Med. Sci. 2020 17 1652 1664 10.7150/ijms.46034 32669967